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1. INTRODUCTION
1.1. Uncharacterized Protein Segments Are a Source of
Functional Novelty
Over the past decade, we have observed a massive increase in the
amount of information describing protein sequences from a
variety of organisms.1,2 While this may reﬂect the diversity in
sequence space, and possibly also in function space,3 a large
proportion of the sequences lacks any useful function
annotation.4,5 Often these sequences are annotated as putative
or hypothetical proteins, and for the majority their functions still
remain unknown.6,7 Suggestions about potential protein
function, primarily molecular function, often come from
computational analysis of their sequences. For instance,
homology detection allows for the transfer of information from
well-characterized protein segments to those with similar
sequences that lack annotation of molecular function.8−10
Other aspects of function, such as the biological processes
proteins participate in, may come from genetic- and disease-
association studies, expression and interaction network data, and
comparative genomics approaches that investigate genomic
context.11−17 Characterization of unannotated and uncharac-
terized protein segments is expected to lead to the discovery of
novel functions as well as provide important insights into existing
biological processes. In addition, it is likely to shed new light on
molecular mechanisms of diseases that are not yet fully
understood. Thus, uncharacterized protein segments are likely
Figure 1. Structured domains and intrinsically disordered regions (IDRs) are two fundamental classes of functional building blocks of proteins. The
synergy between disordered regions and structured domains increases the functional versatility of proteins. Adapted with permission from ref 50.
Copyright 2012 American Association for the Advancement of Science.
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to be a large source of functional novelty relevant for discovering
new biology.
1.2. Structure−Function Paradigm Enhances Function
Prediction
Traditionally, protein function has been viewed as critically
dependent on the well-deﬁned and folded three-dimensional
structure of the polypeptide chain. This classical structure−
function paradigm (Figure 1; left panel) has mainly been based
on concepts explaining the speciﬁcity of enzymes, and on
structures of folded proteins that have been determined primarily
using X-ray diﬀraction on protein crystals. The classical concept
implies that protein sequence deﬁnes structure, which in turn
determines function; that is, function can be inferred from the
sequence and its structure. Even when protein sequences diverge
during evolution, for example, after gene duplication, the overall
fold of their structures remains roughly the same. Therefore,
structural similarity between proteins can reveal distant evolu-
tionary relationships that are not easily detectable using
sequence-based methods.18,19 Structural genomics eﬀorts such
as the Protein Structure Initiative (PSI) have been set up to
enlarge the space of known protein folds and their functions,
thereby complementing sequence-based methods in an attempt
to ﬁll the gap of sequences for which there is no function
annotation.20,21 Speciﬁcally, phase two of the PSI aimed to
structurally characterize proteins and protein domains of
unknown function, often providing the ﬁrst hypothesis about
their function and serving as a starting point for their further
characterization.
1.3. Classiﬁcation Further Facilitates Function Prediction
Classiﬁcation schemes provide a guideline for systematic
function assignment to proteins. Generally, proteins are made
up of a single or multiple domains that can have distinct
molecular functions. These domains, which are referred as
structured domains, often fold independently, make precise
tertiary contacts, and adopt a speciﬁc three-dimensional structure
to carry out their function. The sequences that compose
structured domains can be organized into families of
homologous sequences, whose members are likely to share
common evolutionary relationship and molecular function. The
Pfam database classiﬁes known protein sequences and contains
almost 15 000 such families, for most of which there is some
understanding about the function.22 Nevertheless, Pfam also
contains more than 3000 families annotated as domains of
unknown function, or DUFs.23 These families are largely made
up of hypothetical proteins and await function annotation.
Another powerful example of a protein classiﬁcation scheme is
the Structural Classiﬁcation of Proteins (SCOP), which provides
a means of grouping proteins with known structure together,
based on their structural and evolutionary relationships.24,25
SCOP utilizes a hierarchical classiﬁcation consisting of four
levels, (i) family, (ii) superfamily, (iii) fold, and (iv) class, with
each level corresponding to diﬀerent degrees of structural
similarity and evolutionary relatedness between members. Using
this scheme, function of newly solved structures or sequences can
be inferred from their similarity with existing protein classes
through structure or sequence comparisons, for instance, as
available via the SUPERFAMILY database.10 In this direction,
another major initiative is Genome3D, which is a collaborative
project to annotate genomic sequences with predicted 3D
structures based on CATH26 (Class, Architecture, Topology,
Homology) and SCOP24,25 domains to infer protein function.27
1.4. Intrinsically Disordered Regions and Proteins
While many proteins need to adopt a well-deﬁned structure to
carry out their function, a large fraction of the proteome of any
organism consists of polypeptide segments that are not likely to
Figure 2. The number of protein-coding genes in the human genome
with various amounts of disorder. Histograms of the numbers of human
genes with annotation (A) and without annotation (B), grouped by the
percentage of disordered residues. (C) A comparison of the fraction of
annotated and unannotated human genes with diﬀerent amounts of
disorder. Residues in each protein are deﬁned as disordered when there
is a consensus between >75% of the predictors in the D2P2 database49 at
that position. The set of human genes was taken from Ensembl release
63,1 and the representative protein coded for by the longest transcript
was used in each case. The annotation was taken from the description
ﬁeld with “open reading frame”, “hypothetical”, “uncharacterized”, and
“putative protein” treated as no annotation.
Figure 3. The fraction of disordered residues located in domains in
human protein-coding genes: (A) residues inside (left) and outside
(right) of SCOP domains,24 and (B) residues inside (left) and outside
(right) of Pfam domains (only curated Pfam domains were considered,
i.e., Pfam-A).22 The SCOP domains in human proteins are deﬁned by
the SUPERFAMILY database.10 Disordered residues were taken from
the D2P2 database49 (when there is a consensus between >75% of the
disorder predictors). The set of human genes was taken from Ensembl
release 63.1
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form a deﬁned three-dimensional structure, but are nevertheless
functional.28−42 These protein segments are referred to as
intrinsically disordered regions (IDRs; Figure 1; right panel).43
Because IDRs generally lack bulky hydrophobic amino acids,
they are unable to form the well-organized hydrophobic core that
makes up a structured domain31,44 and hence their functionality
arises in a diﬀerent manner as compared to the classical
structure−function view of globular, structured proteins. In this
framework, protein sequences in a genome can be viewed as
modular because they are made up of combinations of structured
and disordered regions (Figure 1; bottom panel). Proteins
without IDRs are called structured proteins, and proteins with
entirely disordered sequences that do not adopt any tertiary
structure are referred to as intrinsically disordered proteins
(IDPs). The majority of eukaryotic proteins are made up of both
structured and disordered regions, and both are important for the
repertoire of functions that a protein can have in a variety of
cellular contexts.43 Traditionally, IDRs were considered to be
passive segments in protein sequences that “linked” structured
domains. However, it is now well established that IDRs actively
participate in diverse functions mediated by proteins. For
instance, disordered regions are frequently subjected to post-
translational modiﬁcations (PTMs) that increase the functional
states in which a protein can exist in the cell.45,46 In addition, they
expose short linear peptide motifs of about 3−10 amino acids
that permit interaction with structured domains in other
proteins.47,48 These two features in isolation or in combination
permit the interaction and recruitment of diverse proteins in
space and time, thereby facilitating regulation of virtually all
cellular processes.47 The prevalence of IDRs in any genome (see,
for example, the D2P2 database,49 Box 1) in combination with
their unique characteristics means that these regions extend the
classical view of the structure−function paradigm and hence that
of protein function. Thus, functional regions in proteins can
either be structured or disordered, and these need to be
considered as two fundamental classes of functional building
blocks of proteins.50
1.5. The Need for Classiﬁcation of Intrinsically Disordered
Regions and Proteins
IDRs and IDPs are prevalent in eukaryotic genomes. For
instance, 44% of human protein-coding genes contain disordered
segments of >30 amino acids in length49 (similar data shown in
Figure 2A). In the human genome, 6.4% of all protein-coding
genes do not have any function annotation in their description in
Ensembl1 (Figure 2B). Further investigation using the D2P2
database of disorder in genomes49 revealed that most of these
genes with no function annotation encode at least some disorder
(Figure 2B) and that genes with no annotation contain
proportionally more IDRs (Figure 2C). Given the absence of
structural constraints, IDRs tend to evolve more rapidly than
protein domains that adopt deﬁned structures.51−56 As a result,
identifying homologous regions is harder for IDRs and IDPs than
it is for structured domains. This complicates the transfer of
information about function between homologues and thus the
prediction of function of IDRs and IDPs. Furthermore, much of
protein annotation is based on information on sequence families
and structured domains. However, less than one-half of all re-
sidues in the human proteome fall within such domains (Figure 3).
Not only do most residues of human proteins fall outside
domains, a large fraction of these residues are also disordered
(Figure 3A and B, right bars). Moreover, although it is expected
that SUPERFAMILY domains based on known protein
structures have very little disorder (Figure 3A, left bar), Pfam
domains based on sequence clustering do not contain much
more (Figure 3B, left bar). These observations suggest that there
is a large pool of protein segments that are not considered by
conventional protein annotation methods, because the sequen-
ces of disordered regions are diﬃcult to align, or because the
methods do not explicitly consider disordered and nondomain
regions of the protein sequence. Taken together, these
considerations raise the need to devise a classiﬁcation scheme
speciﬁcally for disordered regions in proteins that may enhance
the function prediction and annotation for this important class of
protein segments.
In this Review, we synthesize and provide an overview of the
various classiﬁcations of intrinsically disordered regions and
proteins that have been put forward in the literature since the
start of systematic studies into their function some 15 years ago.
We discuss approaches based on function, functional elements,
structure, sequence, protein interactions, evolution, regulation,
and biophysical properties (Table 1). Finally, we discuss
resources that are currently available for gaining insight into
IDR function (Table 2), we suggest areas where increased eﬀorts
are likely to advance our understanding of the functions of
protein disorder, and we speculate how combinations of multiple
existing classiﬁcation schemes could achieve high quality
function prediction for IDRs, which should ultimately lead to
improved function coverage and a deeper understanding of
protein function.
2. FUNCTION
Dunker and co-workers57 distinguished 28 separate functions for
disordered regions, based on literature analysis of 150 proteins
containing disordered regions of 30 residues or longer. These
functionalities can be summarized as molecular recognition,
molecular assembly, protein modiﬁcation, and entropic chains.
Further development of this scheme resulted in one comprising
six diﬀerent functional classes of disordered protein regions:
entropic chains, display sites, chaperones, eﬀectors, assemblers,
and scavengers (Figure 4).33,58 In another classiﬁcation scheme,
Gsponer and Babu classiﬁed IDR function into three broad
functional categories: (i) facilitated regulation via diverse post-
translational modiﬁcations, (ii) scaﬀolding and recruitment of
diﬀerent binding partners, and (iii) conformational variability
and adaptability (Figure 5).39 A single protein may consist of
several disordered regions that belong to diﬀerent functional
classes.59 The following section will address and exemplify the six
functionalities of disordered regions.
2.1. Entropic Chains
Entropic chains carry out functions that beneﬁt directly from
their conformational disorder; that is, they function without ever
becoming structured. Examples of entropic chains include
ﬂexible linkers, which allow movement of domains positioned
on either ends of the linker relative to each other, and spacers that
regulate the distances between domains. Evidence that ﬂexibility
is a functional characteristic that needs to be maintained came
from studies on a family of ﬂexible linkers in the 70 kDa subunit
of replication protein A (RPA70), which display conserved
dynamic behavior in the face of negligible sequence con-
servation.60 The microtubule-associated protein 2 (MAP2)
projection domain exempliﬁes spacer behavior as it repels
molecules that approach microtubules, thereby providing
spacing in the cytoskeleton. Another subcategory of entropic
chains are entropic springs, such as those present in the titin
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protein, which contains repeat regions rich in PEVK amino acids
that generate force upon overstretching to help restore muscle
cells to their relaxed length.61,62
2.2. Display Sites
Post-translational modiﬁcations (PTMs) aﬀect the stability,
turnover, interaction potential, and localization of proteins
within the cell.63 These aspects of PTMs are particularly relevant
for proteins involved in regulation and signaling, as are many
IDPs.35,37,39,64,65 The conformational ﬂexibility of disordered
protein regions as display sites provides advantages over
structured regions. (i) Flexibility facilitates the deposition of
PTMs by enabling transient but speciﬁc interaction with catalytic
sites of modifying enzymes.47,66 This is because, upon binding, a
ﬂexible, disordered region loses more conformational freedom
(i.e., entropy), which reduces the overall free energy of binding,
leading to weaker and more transient binding as compared to a
folded protein region that interacts with equal strength (i.e., the
same binding enthalpy, or, equal speciﬁcity).28,30,37 (ii) The
ﬂexibility of IDRs also allows for easy access and recognition of
the PTMs within the IDR by eﬀector proteins that mediate
downstream outcomes upon binding.47,66 Indeed, experimental
and computational approaches have shown that disordered
regions are enriched for sites that can be phosphorylated,45,46,67
and suggest that IDPs are likely to be substrates of a large number
of kinases and other modifying enzymes as they are heavily post-
translationally modiﬁed.46,68,69 Furthermore, PTM sites are often
located within short peptide motifs, modiﬁcation of which
inﬂuences the aﬃnity for interaction with diverse binding
partners (see section 3.1).70,71 In turn, disordered protein
regions are strongly enriched for these motifs,47,72−74 under-
lining the importance of intrinsic disorder as PTM display sites.
Well-characterized examples of IDPs in which PTMs are key to
function and regulation include, among others, histones, p53,
and the cyclin-dependent kinase regulator p27.75−77
2.3. Chaperones
Chaperones are proteins that assist RNA and protein molecules
to reach their functionally folded states.78,79 Disordered regions
make up over one-half of the sequences of RNA chaperones and
over one-third of the sequences of protein chaperones.80,81 The
versatility of disordered segments seems well suited for
chaperone function, although mechanistic evidence is still
scarce.82 First, their capacity to structurally adapt to many
diﬀerent binding partners matches the need for chaperones to
bind a wide range of proteins. Second, disordered segments
enable fast macromolecular interactions. This is because the
highly dynamic nature of IDRs prolongs the lifetime of the
encounter complex of the binding event due to rapid sampling of
many diﬀerent conformations, thereby increasing the number of
nonspeciﬁc interactions as compared to an encounter of a
structured protein. In turn, this results in a higher probability to
sample the speciﬁc conformation that results in the stable
interaction complex and increases the association rate of the
interaction.83,84 The quick binding of misfolded proteins by
disordered chaperones could, for example, prevent the formation
of toxic aggregates by providing a solubilizing eﬀect (see
section 9.1). Finally, the binding thermodynamics of disordered
regions are well suited for the cycles of repeated chaperone
binding and release that enable substrate folding. It has been
proposed that transient binding of disordered chaperone regions
to misfolded substrates induces local folding of the disordered
chaperone, and promotes unfolding of the substrate, thereby
providing the substrate with a chance to refold correctly.80 This
reversible exchange of entropy represents a distinct type of
chaperone function that relies on disordered regions and does
not require ATP. Loss of ﬂexibility of disordered regions upon
substrate binding has been demonstrated for the chaperones
GroEL85 and α-crystallin.86,87 This mechanism can even be
switched on and oﬀ at need by regulated transitions between
folded and disordered states,88 as reported in the case of the redox-
regulated chaperone Hsp33.89,90
2.4. Eﬀectors
Another functional class of disordered regions is that of the
eﬀectors, which interact with other proteins and modify their
activity. Upon binding their interaction partners, IDRs often
undergo a disorder-to-order transition, also known as coupled
folding and binding.91,92 Examples of two eﬀectors that fold upon
binding are p21 and p27, which regulate diﬀerent cyclin-
dependent kinases (Cdk) that are responsible for the control of
cell-cycle progression in mammals.66 p21 and p27 exhibit
functional diversity by achieving opposite eﬀects on diﬀerent
Cdk−cyclin complexes, promoting the assembly and catalytic
activity of some (e.g., Cdk4 paired with D-type cyclins), and
inhibiting others (e.g., Cdk2 paired with A- and E-type cyclins).66
Another eﬀector IDP is calpastatin, which undergoes signiﬁcant
folding upon binding calpain, thereby achieving speciﬁc and
reversible inhibition.93
IDRs can also aﬀect the activity of other parts within the same
protein, either through competitive interactions or through
allosteric modulation. The intrinsically disordered GTPase-
binding domain (GBD) of the Wiskott−Aldrich syndrome
protein (WASP) illustrates competitive binding that controls
autoinhibition.94 Binding of the GBD to the Cdc42 protein
promotes the interaction of WASP with the actin cytoskeleton
regulatory machinery. However, GDB adopts a diﬀerent
Figure 4. Functional classiﬁcation scheme of IDRs. The function of
disordered regions can stem directly from their highly ﬂexible nature,
when they fulﬁll entropic chain functions (such as linkers and spacers,
indicated in dark-tone red), or from their ability to bind to partner
molecules (proteins, other macromolecules, or small molecules). In the
latter case, they bind either transiently as display sites of post-
translational modiﬁcations or as chaperones (indicated in green), or
they bind permanently as eﬀectors, assemblers, or scavengers (indicated
in dark-tone blue). More extensive descriptions and examples are found
in the main text. Adapted with permission from ref 58. Copyright 2005
Elsevier.
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structure when it folds back on other parts of WASP to inhibit
actin interaction. Indeed, autoinhibitory regions are generally
enriched for intrinsic disorder and often have diﬀerent structures
in the inhibitory and functionally active states of the protein.95 A
striking example of allosteric coupling in a disordered protein was
revealed between diﬀerent binding sites in the adenovirus E1A
oncoprotein.96 Complexes of E1A with the TAZ2 domain of
CREB-binding protein (CBP) and the retinoblastoma protein
(pRb) can have either positive or negative cooperativity,
depending on the available E1A interaction sites (i.e., binding
of either pRb or CBP to E1A increases or decreases, respectively,
the probability that the other one will also bind). These ﬁndings
support earlier studies that suggest allosteric coupling does not
always require a well-deﬁned structural route to propagate
through the protein, but can also be determined by the stabilities
of individual conformations of the protein that change upon
binding their interaction partners.97−99 Such a mechanism could
be one explanation for how the availability of diﬀerent binding
partners regulates the outcomes of multiple binding events
involving disordered proteins in a cellular context.96
2.5. Assemblers
Disordered assemblers bring together multiple binding partners
to promote the formation of higher-order protein com-
plexes,100,101 such as the ribosome (many ribosomal proteins
are disordered102), activated T-cell receptor complexes,58 the
RIP1/RIP3 necrosome,103 and the transcription preinitiation
complex.104 The presence of diﬀerent functional regions within
the disordered segments, such as molecular recognition features
(MoRFs) and short linear peptide motifs (SLiMs), enables
binding and can bring together diﬀerent partners (see sections
3.1 and 3.2). Indeed, larger complexes are assembled from
proteins that tend to be more disordered,105 and intrinsic
disorder is a common feature of hubs in protein interaction
networks.106,107 The open structure of disordered assemblers is
largely preserved upon scaﬀolding their partner proteins,
resulting in a large binding interface that enables multiple
proteins to be bound by a single IDR.108,109 Furthermore,
disordered regions largely avoid the steric hindrance that
prevents the formation of comparably large complexes from
structured proteins.
Assembler function can be imagined in two ways. (i) The ﬁrst
is structural mortar, which helps to bring together proteins by
stabilizing the complexes they form. A well-studied example of
this behavior is the assembly of the ribosome, which relies on a
sequence of cooperative binding steps of protein and RNA.110
Although the initial stages of rRNA folding are probably driven
by the RNA itself,111 ribosomal proteins subsequently fold upon
binding the rRNAs,112,113 which induces structural changes in
both the RNA and the protein, and guides the complex toward its
native state.110 (ii) The second is scaﬀolds that serve as
backbones for the spatiotemporally regulated assembly of
diﬀerent signaling partners. An example of this mechanism is
the Axin scaﬀold protein, which colocalizes β-catenin, casein
kinase Iα, and glycogen synthetase kinase 3β by their binding to
Axin’s long intrinsically disordered region, thereby eﬀectively
yielding a complex of structured domains with ﬂexible linkers.114
The assembly of all four proteins accelerates interactions
between them by raising their local concentrations and leads to
Figure 5. Functional classiﬁcation of IDRs according to their interaction features. (A) The ﬂexibility of IDRs facilitates access to enzymes that catalyze
post-translational modiﬁcations and eﬀectors that bind these PTMs. This permits combinatorial regulation and reuse of the same components in
multiple biological processes. (B) The availability of molecular recognition features and linear motifs within the IDRs enables the ﬁshing for (“ﬂy
casting”) and gathering of diﬀerent partners. (C) Conformational variability enables a nearly perfect molding to ﬁt the binding interfaces of very diverse
interaction partners. Context-dependent folding of an IDR can activate signaling processes in one case or inhibit them in another, resulting in completely
diﬀerent outcomes. Adapted with permission from ref 39. Copyright 2009 Elsevier.
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the eﬃcient phosphorylation and subsequent destruction of β-
catenin. Scaﬀolding regions have one of the highest degrees of
disorder of all functional categories.109,115
2.6. Scavengers
The ﬁnal distinct functional class of IDRs and IDPs are
scavengers, which store and neutralize small ligands. Chromo-
granin A, one of the earliest examples of an IDP, functions as a
scavenger by storing ATP and adrenaline in the medulla of the
adrenal gland.116 NMR studies showed that chromogranin is a
random coil in both the isolated form and in its cellular
environment in the intact adrenal gland.116 Caseins and other
calcium-binding phosphoproteins (SCPPs) are highly disor-
dered proteins that solubilize clusters of calcium phosphate in
milk and other bioﬂuids (see section 9.3).117 Finally, salivary
proline-rich glycoproteins are scavenger IDPs that bind tannin
molecules in the digestive tract.33
3. FUNCTIONAL FEATURES
Diﬀerent types of functional regions in intrinsically disordered
proteins have been uncovered by investigations aimed both
directly at increasing the understanding of IDRs and indirectly by
linking previously studied functionality of proteins to disordered
regions. First, the majority of linear motifs (such as the SH2
domain interaction motif) have been found as enriched in
IDRs.48,72,118 Second, the development of disorder prediction
methods (Box 3) has led to the identiﬁcation of segments that
promote disorder-to-order transitions called molecular recog-
nition features (MoRFs),119−123 which have been veriﬁed using
known crystal structures. Third, some interaction domains
identiﬁed using crystallography, by sequence analysis, and by
other techniques, turn out to be intrinsically disordered in
solution (e.g., the BH3 domain124). The following section
discusses these three interaction features separately and points
out the underlying connections between them.
3.1. Linear Motifs
A common functional module within IDRs is the linear
motif,47,48,72 also known as LMs, short linear motifs
(SLiMs),125 or MiniMotifs.126 By regulating low-aﬃnity
interactions, these short sequence motifs (annotated instances
are usually 3−10 amino acids long48) can target proteins to a
particular subcellular location, recruit enzymes that alter the
chemical state of the motif by post-translational modiﬁcations
(PTMs), control the stability of a protein, and promote
recruitment of binding factors to facilitate complex forma-
tion.47,48 Linear motifs, helped by the ﬂexible nature of the
disordered regions that surround them,71 primarily bind onto the
surfaces of globular domains,127,128 and their compact binding
surface promotes them to occur multiple times within one
protein.47,48 Moreover, the short nature of many linear motifs
means they have a high propensity to convergently evolve and
emerge in unrelated proteins.47,48 A consequence of these
properties is that pathogenic viruses and bacteria have evolved to
mimic these linear motifs, allowing them to manipulate
regulation of cellular processes.129,130
Linear motifs can be broadly divided into two major families:
those that act as modiﬁcation sites and those that act as ligands,
with each having numerous subgroups (Figure 6).131 The ﬁrst
major family, the enzyme binding or modiﬁcation motifs, can be
divided into three groups. (i) The ﬁrst is post-translational
processing events or proteolytic cleavage. A well-known example
is the motif recognized by Caspase-3 and -7, which has an [ED]
xxD[AGS] consensus sequence. Caspases are a family of
proteases that promote apoptosis and inﬂammation by cleaving
such motifs in their substrate proteins.132 Hundreds of proteins
have convergently evolved the Caspase-3/-7 motif, and thereby
have come under the regulation of the apoptotic pathway.133 (ii)
The second is PTMmoiety removal and addition.Many enzymes
that catalyze post-translational modiﬁcations recognize a speciﬁc
binding sequence on the substrate. For example, the cyclin-
dependent kinase recognition motif [ST]Px[KR] is present in
many mitotic proteins, and its phosphorylation is key for
regulating cell cycle progression.134 (iii) The third is structural
modiﬁcations. This group of motifs is involved in the catalyzed
conformational alteration of a peptide backbone. The classic
example is the peptidylprolyl cis−trans isomerase (PPIase) Pin1,
which binds [ST]P motifs in a phosphorylation dependent
manner to catalyze the cis−trans isomerization of the proline
peptide bond. This modiﬁcation can regulate the recognition of
phosphorylated [ST]P sites by phosphatases.135
The second major family of motifs comprises ligand motifs,
which can also be divided into three main groups (Figure 6). (i)
Complex promoting motifs are the most well-known class of
motifs and include the phosphorylated tyrosine motif recognized
by SH2 (Src homology 2) domains, the C-terminal motifs that
bind PDZ domains, and the proline-rich PxxPmotifs that interact
with SH3 (Src homology 3) domains.136 These motifs often
function in protein scaﬀolding, and their multivalency (tendency
to occur multiple times in one sequence) can increase the avidity
of interactions and promote phase transition (see section 9.2).137
(ii) Docking motifs increase the speciﬁcity and eﬃciency of
modiﬁcation events (e.g., addition or removal of PTMs, see
above) by providing additional binding surface. These docking
motifs are distinct from the modiﬁcation sites, but are usually in
the same protein. Examples are the KEN box and D box degrons,
which act as recognition surfaces for ubiquitin ligases that
ubiquitinate the protein on a diﬀerent position, leading to
degradation of the protein by the 26S proteasome.138,139 The
KEN box motif occurs in several key mitotic kinases to ensure
their degradation or deactivation at mitotic exit.139 In some cases,
the docking site is present in a protein diﬀerent from that which
contains the modiﬁcation site, as exempliﬁed by the F box motif.
Another part of F box proteins recognizes post-translationally
modiﬁed degradation motifs of substrates, while the F box itself
docks the Skp1 components of SCF (Skp, Cullin, F box) E3
ligase complexes.140 (iii) Targeting motifs can localize proteins
toward subcellular organelles. For example, importin proteins
involved in nuclear transport recognize the nuclear localization
signal (NLS), usually a motif containing a short cluster of lysines
and arginines, and translocate NLS-containing proteins into the
nucleus.141 Targeting motifs can also act to traﬃc proteins, as in
the case of endocytic motifs. These are recognized by adaptor
proteins at diﬀerent stages of endocytosis to ensure that cargo
proteins are packaged into vesicles and traﬃcked to the right
location.142,143
An important feature of linear motifs is their propensity to act
as molecular switches. This is for two major reasons. (i) Linear
motif-mediated interactions are generally low aﬃnity due to the
limited binding surface. This means that large, bulky post-
translational modiﬁcations have a big impact on their binding
properties.71 (ii) Their small footprint (i.e., size) allows motifs to
occur multiple times in the same protein, thereby promoting high
avidity interactions and the recruitment of multiple factors (e.g.,
the LAT complex in T-cell receptor signaling144).99 This also
means two diﬀerent motifs can overlap, resulting in mutually
exclusive binding of interaction partners.73 The ability of a motif
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Figure 6. Functional classiﬁcation of linear motifs. Linear motifs can be divided into two major families, which each have three further subgroups. The
modiﬁcation class motifs all act as recognition sites for enzyme active sites, whereas the ligand class motifs are always recognized by the binding surface of
a protein partner. More detailed classiﬁcation beyond the graph shown here is possible. For example, an important subgroup of docking motifs are the
degrons, which regulate protein stability by recruiting members of the ubiquitin−proteasome system. In the regular expressions, x corresponds to any
amino acid, while other letters represent single letter codes of amino acids; letters within square brackets mean either residue is allowed in that position.
Figure 7.Classiﬁcation of molecular recognition features (MoRFs) based on the secondary structure of the bound state. MoRFs (red ribbons) undergo
disorder-to-order transition upon binding their partners (blue surfaces). (A) α-MoRF. BH3 domain of BAD (MoRF) bound to bcl-xl (partner) (PDB
ID: 1G5J). (B) β-MoRF. Inhibitor of apoptosis protein DIAP1 (partner) bound to N-terminus of cell death protein GRIM (MoRF) (PDB ID: 1JD5).
(C) ι-MoRF. AP-2 (partner) bound to the recognition motif of amphiphysin (MoRF) (PDB ID: 1KY7). (D) Complex-MoRF. Phosphotyrosine-
binding domain (PTB) of the X11 protein (partner) bound to amyloid β A4 protein (MoRF) (PDB ID: 1X11). Note that the PTB domain of X11
actually binds unphosphorylated peptides and is a PTB by sequence similarity. Panels A−D reprinted with permission from ref 122. Copyright 2007
American Chemical Society. (E) Promiscuity of disorder-controlled interactions illustrated by the p53 interaction network. A structure versus disorder
prediction on the p53 amino acid sequence is shown in the center of the ﬁgure (up = disorder, down = order) along with the structures of various regions
of p53 bound to 14 diﬀerent partners. The predictions for a central region of structure, and the disordered amino and carbonyl termini have been
conﬁrmed experimentally for p53. The various regions of p53 are color coded to show their structures in the complex and to map the binding segments
to the amino acid sequence. Starting with the p53−DNA complex (top, left, magenta protein, blue DNA), and moving in a clockwise direction, the
Protein Data Bank147 IDs and partner names are given as follows for the 14 complexes: (1tsr − DNA), (1gzh − 53BP1), (1q2d − gcn5), (3sak − p53
(tetramerization domain)), (1xqh − set9), (1h26 − cyclin A), (1ma3− sirtuin), (1jsp − CBP bromo domain), (1dt7− s100ββ), (2h1l − sv40 Large T
antigen), (1ycs − 53BP2), (2gs0 − PH), (1ycr − MDM2), and (2b3g − RPA70). Reprinted with permission from ref 40. Copyright 2010 Elsevier.
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to rapidly switch between binding partners and create multi-
valent complexes is crucial for the creation of dynamic signaling
networks.71
3.2. Molecular Recognition Features
Disordered segments can also contain another type of peptide
motif (10−70 amino acids) that promotes speciﬁc protein−
protein interactions. These functional elements are called
preformed structural elements (PSEs),119 molecular recognition
features (MoRFs) or elements (MoREs),120−122 or prestruc-
tured motifs (PreSMos).123 Importantly, MoRFs undergo
disorder-to-order transitions upon binding their interaction
partners (i.e., folding upon binding),38,121,123 and often the
unbound form of these preformed elements is biased toward the
conformation that they adopt in the complex.119 Preformed
structural elements and MoRFs may serve as initial contact
points for interaction events, which have diﬀerent kinetic and
thermodynamic properties than interactions between structured
protein regions as discussed before. Binding of preformed
elements is one version of conformational selection (see
section 6), suggested long ago for interactions with ﬂexible
ligands.145 At the other extreme is induced folding, in which
structure formation and binding occur concomitantly after the
formation of the initial encounter complex. Given the complexity
of many complexes involving intrinsically disordered regions,
interactions involving both conformational selection of pre-
formed elements and induced folding likely occur.92,146
MoRFs occurring in the Protein Data Bank147 can be classiﬁed
into subtypes according to the structures they adopt in the bound
state: α-MoRFs, β-MoRFs, and ι-MoRFs (Figure 7A−C),121
which form α-helices, β-strands, and irregular (but rigid)
secondary structure when bound, respectively. MoRFs that
contain combinations of diﬀerent types of secondary structure
are called complex (Figure 7D).121 The p53 protein contains
multiple MoRFs that are disordered in the absence of their
interactors (Figure 7E).120,121 The ﬁrst p53MoRF is located near
the N-terminus and undergoes a transition from a disordered to
an α-helical state upon interaction with the Mdm2 protein. In
fact, this region of p53 exempliﬁes the high potential of IDRs for
multiple partner binding as it is known to bind more than 40
diﬀerent partners. However, for most of these complexes, the 3D
structures are not determined, and therefore the MoRF type is
not always known. The region between p53 residues 40 and 60
features an α-MoRF that functions as a secondary binding site for
Mdm2 as well as a primary binding site for RPA70.148 In the
absence of any binding partner, this region shows evidence of
minimal helical secondary structure,149 whereas when bound to
either Mdm2150 or RPA70,151 a stronger helical structure is
observed. The C-terminal region of p53 also contains a MoRF
that interacts with multiple partners, giving rise to diﬀerent
bound structures. For example, the S100B(ββ) protein induces a
helical structure, while interaction with the Cdk2−cyclin A
complex leads to an irregular ι-MoRF. An example of the role of
MoRFs in scaﬀolding proteins is RNase E, which assembles the
RNA degradosome.152 The ﬂexible C-terminal end of RNase E
contains several recognition motifs that are central to its
scaﬀolding function and serve as binding sites for other members
of the degradosome.153 For example, an α-MoRF interacts with
enolase,154 and a β-MoRF binds polynucleotide phosphor-
ylase.155 The recognition features are connected by disordered
segments that accommodate assembly of the multiprotein
complex by providing the required space and ﬂexibility. Lee
and co-workers123 have annotated the secondary structure
propensities of many other regions that display transient
structural elements and undergo disorder-to-order transitions,
all of which have been experimentally conﬁrmed by NMR
spectroscopy.
Sequence context can play an active role in modulating the
degree of structural preorganization of a MoRF. An example
pertains to the study of DNA binding motifs in the basic regions
(bRs) of basic region leucine zipper transcription factors.156 The
bRs are 28−30 residue long regions predicted to be highly
disordered and include a strongly conserved 10-residue DNA
binding motif (DBM). The α-helicity (i.e., preference for α-
helical conformation) of the DBM in the unbound form is
modulated by the sequence of the N-terminal segment that is
directly in cis to the DBM.156 For example, the N-terminal
sequence contexts of Gcn4 and Cys3 DBMs contribute to a
higher level of helicity of the DBM than the same region in c-Fos
and Fra1 (whose DBMs have a low helicity). Essentially, the N-
terminal sequence contexts are helix caps, and these can be used
in diﬀerent ways to ensure diﬀerent levels of structural
preorganization within an α-MoRF, thereby suggesting that
investigating sequence contexts can provide useful clues when
classifying MoRFs and linear motifs.157
3.3. Intrinsically Disordered Domains
Most protein domains that are identiﬁed using sequence-based
approaches are structured, but some can be fully or largely
disordered158 or contain conserved disordered regions,159
known as intrinsically disordered domains (IDDs). For instance,
about 14% of Pfam domains have more than 50% of their
residues in predicted disordered regions. Many well-known
domains, such as the kinase-inhibitory domain (KID) of Cdk
inhibitors (e.g., p2766) and the Wiskott−Aldrich syndrome
protein (WASP)-homology domain 2 (WH2) of actin-binding
proteins,158 have been shown experimentally to be fully
disordered in isolation and solution. Protein domains with
conserved disordered regions have a variety of functions, but are
most commonly involved in DNA, RNA, and protein binding.159
Furthermore, domains that were gained during evolution by the
extension of existing exons contain the highest degree of
disordered regions.160 This suggests that exonization of
previously noncoding regions could be an important mechanism
for the addition of disordered segments to proteins.
Interestingly, it has also been observed that particular
disordered regions frequently co-occur in the same sequence
with speciﬁc protein domains.161,162 Some domain families
appear only to require the presence of disorder in their
neighborhood for functioning, while others seem to rely on the
occurrence of disordered regions in speciﬁc locations relative to
the start or end of the protein domain.161 For example, particular
combinations of domains, involvedmainly in regulatory, binding,
receptor, and ion-channel roles, only occur with a disordered
region inserted between them, while others only occur without a
disordered domain between them. These observations imply that
short disordered regions in the vicinity of protein domains
complement the function of a structured domain, and in some
cases may comprise separate functional modules in their own
right. Thus, the co-occurrence of IDRs and structured domains in
the same protein might be useful to gain insight into unannotated
disordered regions.
3.4. Continuum of Functional Features
A measure that is often used to distinguish the diﬀerent types of
disordered binding modules is length; however, this is likely to
stem primarily from the diﬀerent methodology used for their
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detection. Protein domain detection relies on hidden Markov
models,22 which is not the best approach for identifying short
sequences, and therefore domain annotation tends to focus on
larger sequence regions. In contrast, linear motifs in the ELM
database are biased toward short binding modules (∼3−10
amino acids48,125) as these are more straightforward to annotate.
Finally, the tendency of MoRFs and preformed elements to
undergo disorder-to-order transitions and the statistics used for
their detection means that these features tend to be slightly
longer than annotated linear motifs.
Thus, although there are diﬀerences in the deﬁnitions of linear
motifs and MoRFs, they share many common features72,163
including a tendency to undergo disorder-to-order transition (all
MoRFs by deﬁnition and ∼60% of LMs48), an enrichment in
IDRs (MoRFs by deﬁnition and ∼80% of LMs are in IDRs48,72),
and a tendency to promote complex formation.48,100,122
Intrinsically disordered domains (IDDs) can also have signiﬁcant
overlap with MoRFs and linear motifs. For example, the WH2
domain is considered an IDD158 and is also deﬁned as a motif in
the ELM database.125 One feature that is probably more
common in IDDs is that some are not only capable of binding
to well-folded, structured domains (a mechanism shared with
motifs and MoRFs), but can also bind each other in a process of
mutually induced folding. For example, the nuclear coactivator
binding domain (NCBD) of CREB-binding protein (CBP) and
the activator for thyroid hormone and retinoid receptors
(ACTR) domain of p160 are both disordered on their own but
upon interaction form a complex by mutual synergistic
folding.164 The overlap between linear motifs and MoRFs
especially, but also IDDs, suggests that these functional features
are diﬀerent states in the same continuum of binding
mechanisms involving disordered regions.
4. STRUCTURE
Intrinsically disordered regions and proteins show a wide variety
of structural subtypes. These diﬀerent types of disorder can be
characterized using an array of experimental techniques (Box 2),
and several resources collect computationally identiﬁed and
experimentally veriﬁed disordered regions (Box 1). The
following section discusses classiﬁcation schemes that are
based on structural features of disordered proteins.
4.1. Structural Continuum
Proteins have been proposed to function within a conformational
continuum, ranging from fully structured to completely
disordered.37 The spectrum covers tightly folded domains that
display either no disorder or only local disorder in loops or tails,
multidomain proteins linked by disordered regions, compact
molten globules containing extensive secondary structure,
collapsed globules formed by polar sequence tracts, unfolded
states that transiently populate local elements of secondary
structure, and highly extended states that resemble statistical coils
(Figure 8). In this model, there are no boundaries between the
described states and native proteins could appear anywhere within
the continuous landscape. IDRs are highly dynamic and ﬂuctuate
rapidly over an ensemble of heterogeneous conformations (see
section 4.2).165 Thus, an IDR may ﬂuctuate stochastically between
several diﬀerent states, transiently sampling coil-like states, localized
secondary structure, and more compact globular states. Transient
localized elements of secondary structure (most often helices) are
common in amphipathic regions of the sequence and potentially
play a role in binding processes.92 The structural characteristics and
populations of the individual states in the conformational ensemble
and the degree of compaction of the polypeptide chain are
determined by the nature of the amino acids and their distribution
in the IDR sequence (see section 5.1).166−168 For example, low and
high average charges typically lead to disordered globules and
swollen coils, respectively.166,167
4.2. Conformational Ensembles
Disordered regions in the native unbound state exist as dynamic
ensembles of rapidly interconverting conformations,165,169,170
which can be described by relatively ﬂat energy land-
scapes.99,171,172 Conditions, post-translational modiﬁcations,
and binding events (see section 6) change the relative free
energies of individual conformations as well as the energy
diﬀerences between conformations.99,173−176 As a result, the
populations of individual conformations within the ensemble
Figure 8. Schematic representation of the continuum model of protein
structure. The color gradient represents a continuum of conformational
states ranging from highly dynamic, expanded conformational
ensembles (red) to compact, dynamically restricted, fully folded
globular states (blue). Dynamically disordered states are represented
by heavy lines, stably folded structures as cartoons. A characteristic of
IDPs is that they rapidly interconvert between multiple states in the
dynamic conformational ensemble. In the continuum model, the
proteome would populate the entire spectrum of dynamics, disorder,
and folded structure depicted.
Figure 9.The protein quartet model of protein conformational states. In
accordance with this model, protein function arises from four types of
conformations of the polypeptide chain (ordered forms, molten
globules, pre-molten globules, and random coils) and transitions
between any of these states.
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change under diﬀerent conditions. These individual states are
often important for function. Thus, the dynamic nature of IDPs is
best modeled by statistical approaches that describe the
probabilities of individual conformations in the ensem-
ble,172,177,178 and is best measured by experimental techniques
that prevent conformational averaging (Box 2).179−182
4.3. Protein Quartet
The protein quartet model proposes that protein function can
arise from four types of conformational states and the transitions
between them: random coil, pre-molten globule, molten globule,
and folded (Figure 9).32,34 In this model, unbound disordered
regions could fall into all categories except for “folded”. Proteins
in the pre-molten globule state are less compact than molten
globules, but still show some residual secondary structure. In
contrast, proteins in the random coil state show little or no
secondary structure. The pre-molten globule state has a high
propensity to participate in folding upon binding events,183
which would make this structural state suitable for disordered
regions acting as eﬀectors and scaﬀolds. On the basis of the
notion that IDPs and IDRs possess great structural and sequence
heterogeneity, proteins may also be considered as modular
assemblies of foldons (independently foldable regions),
inducible foldons (foldable regions that can gain structure as a
result of interaction with speciﬁc partners), semifoldons (regions
that are always partially folded), and nonfoldons (regions that
never fold).184 The four distinct conformational states of the
quartet model are a subset of the continuous spectrum of
diﬀerently disordered states (see section 4.1),37 which extends
from fully ordered to completely structure-less proteins, with
everything in between. A single description of structure (such as
the quartet states) may be suitable for the conformational
average of a protein, while a structural continuum is a better
description of an ensemble of diﬀerent conformations (see
section 4.2).
FG nucleoporins are an example of the functional signiﬁcance
that diﬀerent disordered conformations can have. The porins
make up the central part of nuclear pore complexes (NPCs) and
regulate nucleocytoplasmic transport.185 Intrinsically disordered
regions with multiple phenylalanine-glycine (FG) motifs make
up large parts of the NPC gates. FG regions adopt various
disordered conformations with speciﬁc functions.186 Some
regions have the low charge characteristics of collapsed coils,
while others are characterized by a high degree of charged amino
acids, giving rise to relaxed and extended coil structures.
Molecular dynamics simulations have shown that extended
coils are more dynamic than collapsed coils, suggesting distinct
functionalities for the two structural groups. Interestingly, some
FG nucleoporins feature both types of disorder along their
polypeptide chain. Combinations of disorder subtypes in
nucleoporin domains are likely to contribute to NPC gating
behavior by creating “traﬃc” zones with distinct physicochemical
properties that inﬂuence the dynamics of substrate translocation
through the nuclear envelope.186−189
4.4. Supertertiary Structure
IDRs allow for complex regulatory phenomena, as witnessed in
the case of multidomain proteins in signaling and regula-
tion.39,66,70,71,136,190 Because of the presence of structural
disorder, functional domains, and short motifs, multidomain
proteins are characterized by a dynamic ensemble of tertiary con-
formations. Some conformations are dominated by intramolecular
domain−domain and domain−motif interactions and are closed
and structured in nature, while other conformations aremore open
and disordered. This state of conformational variability within a
protein lies between the tertiary structure of proteins and the
quaternary structure of multiprotein assemblies, and has been
termed supertertiary structure.191 Complex regulatory function
stems from transitions in the ensemble of these structures, as
demonstrated by several well-characterized proteins, such as the
Wiskott−Aldrich syndrome protein (WASP, see section 2.4),94
the Src-family tyrosine kinase Hck,192 and the E3 ubiquitin ligase
Smurf2.193
5. SEQUENCE
The sequences of IDPs and IDRs have distinct compositional
biases. They are enriched in charged and polar amino acids and
depleted in bulky hydrophobic groups.31,44,194,195 These biases
have led to the inference that disorder is a natural consequence of
weakening the hydrophobic eﬀects that drive folding of
polypeptides into compact tertiary structures. Although
disordered regions generally lack the ability to fold independ-
ently due to these biases in amino acid composition, distinct
subsets of sequences that have diﬀerent structural and functional
characteristics can be identiﬁed within IDRs. The special
sequence properties of disordered regions are the basis for
many disorder prediction methods (Box 3). The following
section covers sequence-based classiﬁcation schemes of IDRs.
5.1. Sequence−Structural Ensemble Relationships
Systematic eﬀorts combining experiments and computations
have addressed the relationship between information encoded in
amino acid sequences and the ensemble of conformations (see
section 4.2) these sequences can sample in diﬀerent conditions.
These studies have focused on three major archetype sequences:
polar tracts, polyelectrolytes, and polyampholytes.196 Polar tracts
are sequence stretches enriched in polar amino acids such as
glutamine, asparagine, serine, glycine, and proline, and deﬁcient
in charged as well as hydrophobic residues. These polar tracts
(especially glutamine, asparagine, and glycine-rich sequences)
form globules that are generally devoid of signiﬁcant secondary
structure preferences170,197−199 and can be as compact as well-
folded domains.196 Collapse of polar tracts arises from the
preference for self-solvation over solvation by the aqueous
milieu. In this case, disorder derives from a lack of speciﬁcity for a
single compact conformation as instead heterogeneous ensem-
bles of conformations with similar stabilities and compactness are
formed. The free energy landscape of polar tracts is weakly
funneled and resembles an “egg carton”.200 Interestingly, the
drive to collapse, which implies a drive to minimize the interface
between the IDR and the surrounding solvent, can also give rise
to the signiﬁcant aggregation and solubility problems201 as is the
case with several glutamine, asparagine, and glycine-rich
sequences that are implicated in amyloid formation and phase
separation.202
Another end of the compositional spectrum are polyelec-
trolytes. Their amino acid compositions are biased toward
charged residues of one type such as the arginine-rich
protamines166 or the Glu/Asp-rich prothymosin α.167 Experi-
ments and simulations have shown that the tendency of
polypeptide backbones to form ensembles of collapsed structures
can be reversed by increasing the net charge per residue past a
certain threshold (Figure 10A). The transition between globules
and expanded coils is sharp, suggesting that small changes to the
net charge per residue through post-translational modiﬁcations
such as serine or threonine phosphorylation or lysine acetylation
could cause reversible globule-to-coil transitions. These
Chemical Reviews Review
dx.doi.org/10.1021/cr400525m | Chem. Rev. 2014, 114, 6589−66316602
transitions might control the accessibility of SLiMs and MoRFs
or even modulate the conformations of these elements.
The impact of the net charge per residue on the conforma-
tional properties of IDRs can be summarized in a diagram-of-
states (Figure 10A),166 which generalizes the original charge-
hydropathy plot.31 The diagram classiﬁes IDRs on the basis of
their amino acid compositions. Annotation using curated
disordered sequences from the DisProt database203 (Box 1)
initially suggests that a vast majority (∼95%) of IDPs have amino
acid compositions that predispose them to be globule formers
(Figure 10A).204 However, most of these predicted globule
formers are actually polyampholytes in that they are enriched in
charged residues but have roughly equal numbers of positive and
negative charges.204 Although such sequences are classiﬁed as
globule formers on the basis of their low net charge per residue,
in reality the conformational properties of polyampholytes are
governed by the linear sequence distribution of oppositely
charged residues. If the oppositely charged residues are
segregated in the linear sequence, then electrostatic attractions
between oppositely charged blocks cause chain collapse and
result in hairpin or globular conformations. In sequences with
well-mixed oppositely charged residues, the eﬀects of electro-
static repulsions and attractions counterbalance. These mixed
sequences adopt random-coil or globular conformations,
depending on the total charge (in terms of the fraction of
charged residues) (Figure 10B). Many IDPs are strong
polyampholytes with well-mixed linear patterns of oppositely
charged residues.204 Thus, IDPs are actually enriched in diﬀerent
classes of random coils that form swollen, loosely packed
conformations (Figure 10B). Such random-coil sequences are
likely to help improve the solubility proﬁles of connected
structured domains (see section 9.1) and to promote the
ﬂexibility that is required for functions such as entropic tethers,
which promote high local concentrations of connected protein
parts, or entropic bristles, which occupy large volumes by rapid
exploration of conformations. These biophysical principles of
sequence−structural ensemble relationships enable the use of de
novo sequence design as a tool for modulating these properties
and assessing their impact on functions associated with IDPs and
IDRs.
Figure 10.Original166 and modiﬁed204 diagram-of-states to classify predicted conformational properties of IDPs (and IDRs modeled as IDPs). (A) The
original diagram predicts that sequences with a net charge per residue above 0.25 will be swollen coils. The three axes denote the fraction of positively
charged residues, f+, the fraction of negatively charged residues, f−, and the hydropathy. All three parameters are calculated from the amino acid
composition. Green dots correspond to 364 curated disordered sequences extracted from the DisProt database.203 These sequences have hydropathy
values that designate them as being disordered; that is, they lie in the bottom portion of the pyramid by deﬁnition. Additional ﬁlters were used for chain
length (more than 30 residues) and the fraction of proline residues ( f pro < 0.3). 97% of sequences used in this annotation have a net charge per residue of
less than 0.26 and are thus predicted to be globule formers.204 Adapted from ref 166. Copyright 2010 National Academy of Sciences of the United States
of America. (B) Modiﬁed diagram-of-states from panel (A) with a focus only on the bottom portion of the pyramid (i.e., stipulating that the hydropathy
is low enough to be ignored).204 The polyampholytic contribution expands the space encompassed by nonglobule-formers by subdividing the
disordered globules space in panel (A) into three distinct regions of which sequences in regions 2 and 3 actually may not form globules. In these
polyampholytic regions, one has to account for the total charge, in terms of the fraction of charged residues (FCR), as well as the net charge per residue
(NCPR) as opposed to NCPR alone. Conformations in regions 2 and 3 are expected to be random-coil-like if oppositely charged residues are well mixed
in the linear sequence. Otherwise, one can expect compact or semicompact conformations. The classiﬁcation scheme uses only the amino acid sequence
as input. Reprinted with permission from ref 204. Copyright 2013 National Academy of Sciences of the United States of America.
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5.2. Prediction Flavors
Methods for predicting disordered regions have generally been
successful (Box 3), but their prediction accuracies vary for
diﬀerent types of disordered regions.205 Some predictors
accurately predict certain disordered regions but have lower
accuracy predicting others, whereas other predictors give
opposite results. Vucetic and co-workers205 classiﬁed protein
disorder into three diﬀerent “ﬂavors” based on competition
between disorder predictors. These V, C, and S disorder ﬂavors
(corresponding to the names of the disorder predictors that best
predict them: VL-2V, VL-2C, and VL-2S) show diﬀerences in
sequence composition, and combinations of ﬂavors could be
associated with diﬀerent protein functions. For example,
disordered regions that bind to other proteins are enriched for
ﬂavor S, while disordered ribosomal proteins predominantly
belong to ﬂavor V. Flavor C gave strong disorder predictions for
sugar binding domains.
5.3. Disorder−Sequence Complexity Space
The relationship between sequence complexity and disorder
propensity provides further insight into the structural and
functional variations of IDRs.206 Diﬀerent functional classes of
proteins often show a diﬀerent disorder−sequence complexity
(DC) space distribution. A frequently observed DC-distribution
is composed of a compact structured part and a section extending
out into the low-complexity and high-disorder space before
looping back into the structured region. This pattern describes a
disordered linker region between structured domains. An
example is the bacterial translation initiation factor, which
contains a sequence that locates to the low-complexity, high-
disorder region of DC space. This loop connects the N- and C-
terminal domains, which are high-structure and high-complex-
ity.206,207 Functionally related proteins have similar disorder−
sequence complexity distributions, suggesting that these
distributions might be useful for predicting the function of a
disordered region.
5.4. Overall Degree of Disorder
Large-scale studies into IDP function often group the proteins on
the basis of some measure of disorder. For example, protein
sequences have been categorized on the basis of the overall
degree of disorder (i.e., the fraction of residues that is shown or
predicted to be disordered),68,208 resulting in groups of
structured proteins (0−10% disorder), moderately disordered
proteins (10−30% disorder), and highly disordered proteins
(30−100% disorder). For 24% of human protein-coding genes,
at least 30% of residues are predicted to be disordered
(Figure 2A). Other studies classiﬁed proteins on the basis of an
overall score of disorder for the whole protein,209 and the presence
or absence of continuous stretches of disordered residues with a
speciﬁc length.35,51,161,208 Largely structured proteins are enriched
for metabolic functions, while highly disordered proteins function
predominantly in regulation. Hence, classiﬁcation of disordered
proteins based on the level of disorder provides clues about what
types of functions are likely.
5.5. Length of Disordered Regions
The length of IDRs in human follows a power law distribution:
there are large numbers of short disordered regions and
increasingly smaller numbers of longer ones.210 Other eukaryotic
and prokaryotic proteomes show similar disorder length proﬁles.
44% of human protein-coding genes contain substantial
disordered segments of >30 amino acids in length49 (similar
data shown in Figure 2A). Short IDRs may function as linkers
and contain individual linear motifs or MoRFs, whereas longer
disordered regions might be entropic chains or contain
combinations of motifs or domains functioning in recognition.
Very long disordered regions (more than 500 residues) are
typically over-represented in transcription-related functions,211
whereas proteins containing IDRs of 300−500 residues in length
are enriched for kinase and phosphatase functions. Shorter IDRs
(less than 50 residues) tend to be linked to metal ion binding, ion
channels, and GTPase regulatory functions. Thus, the length of a
disordered region can also provide a useful indication about the
functional nature of the protein containing it.
5.6. Position of Disordered Regions
Almost all human proteins have some disordered residues within
their terminal regions.59 For example, 97% of proteins have
predicted disorder in the ﬁrst or last ﬁve residues.161 Disordered
N-terminal tails are common in DNA-binding proteins, and have
been shown to contribute to eﬃcient DNA scanning.212
Furthermore, proteins that are relatively rich in disordered
residues at the C-terminus are often associated with transcription
factor repressor and activator activities as compared to proteins
rich in internal or N-terminal disorder.211 Membrane proteins,
depending on their topology of insertion, also contain disordered
regions in the N- or C-terminus, but their sequence composition
is diﬀerent as compared to disordered regions in cytosolic
proteins.213 Ion channel proteins are enriched for disordered
residues at the N-terminus, and the same is true to a lesser extent
for C-terminal disorder.211 These terminal disordered regions are
often functionally relevant, as illustrated by their role in the
inactivation of voltage-gated potassium channels.214 Similarly,
many G-protein-coupled receptors (GPCRs) have large
disordered regions in their C-terminus, and often in the
intracellular loops.215 Several of them harbor peptide motifs
that link ligand binding in the transmembrane region of the
receptor to intracellular eﬀectors, or contain PTM sites or linear
motifs that govern their stability.216 Finally, proteins that are
relatively rich in internal disordered regions are weakly enriched
for transcription regulator and DNA binding activity.211 Thus,
the relative position of a disordered region in a sequence provides
clues about the function of the protein containing it.
5.7. Tandem Repeats
Short tandem repeats are common in IDRs and IDPs.61,217−220
For instance, as much as 96% of polyglutamate and polyserine
stretches lie within disordered regions.219 Similarly, large
fractions were found for proline, glycine, glutamine, lysine,
aspartate, arginine, histidine, and threonine repeats. In contrast,
polyleucine stretches occur predominantly within structured
regions. These observations agree with the compositional bias of
disordered regions (see section 5.1); the most common tandem
repeats in IDRs are made up of disorder-promoting residues44,194
and of sequence patterns that are typically associated with
disorder.195 Moreover, a distinction between perfect and
imperfect tandem repeats suggests that as the repeat perfection
increases, so does the disorder content.219
Repeats of diﬀerent composition have been linked to speciﬁc
functions.218,221 Consequently, the presence of particular types
of repeats is likely to contribute to IDR functioning. Descriptions
and examples of diﬀerent classes of disordered tandem repeats
and their structural characteristics have been reviewed
previously.218 For instance, polyproline and polyglutamine
stretches are associated with protein and nucleic acid binding
and transcription factor activity.222,223 Protein segments
enriched for glutamine and asparagine often occur in disordered
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regions224 and are abundant in eukaryotic proteomes,225 despite
their propensity to aggregate or form coiled-coil structures.226
The aggregation propensity of the Q/N-enriched segments is
exploited in the formation of physiologically relevant assemblies
such as P-bodies (e.g., Ccr4 and Pop2), stress granules, and
processing bodies.227 However, expanded polyglutamine repeats
are also associated with neurodegenerative disorders, the most
well-known being Huntington’s disease.228 Moreover, several
prion-like yeast proteins (e.g., Sup35p and Ure2p) contain
intrinsically disordered Q/N-rich protein segments that have
been implicated in the switch between a soluble and an insoluble,
aggregated form.225,229 Another example of functional disor-
dered repeats occurs in the SR protein family of splicing factors
(e.g., ASF/SF2 and SRp75).230,231 SR proteins mediate the
assembly of spliceosome components. They consist of an N-
terminal RNA-recognition motif and a disordered C-terminus
with tandem repeats of arginine and serine residues (RS
domain). Phosphorylation switches the RS domain of the
serine/arginine-rich splicing factor 1 (SRSF1) from a fully
disordered state to a more rigid structure.232 Other disordered
repeats associated with a speciﬁc function include sequences
enriched in lysine, alanine, and proline in the histone H1 C-
terminal domain, which are involved in the formation of 30 nm
chromatin ﬁber by binding linker DNA between the
nucleosomes.233,234 A ﬁnal example is dentin sialophosphopro-
tein (DSPP), which contains extensively phosphorylated repeats
of aspartic acid and serine involved in calcium phosphate binding
(see section 9.3).235 Some repeat-containing regions are also
prone to undergo phase transitions from a soluble monomeric
state to an insoluble large assembly form, as demonstrated for
regions rich in proline, threonine, and serine residues in mucins
(see section 9.2).236
6. PROTEIN INTERACTIONS
Disordered region-mediated molecular interactions have been
proposed to work using a combination of conformational
selection and induced folding.92,146,237 These mechanisms of
binding are two extreme possibilities and are not mutually
exclusive. Both play a role in the interaction between two
proteins, the dominant mechanism depending, for example, on
Figure 11. Classiﬁcation of fuzzy complexes by topology (upper panel) and by mechanism (lower panel). Blue arrows indicate interactions between
fuzzy disordered regions and structured molecules. Protein Data Bank147 identiﬁers for the structures are given in parentheses. Topological categories:
(A) Polymorphic. TheWH2 domain of ciboulot interacts with actin in alternative locations: via an 18-residue segment (3u9z) or via only three residues
(2ﬀ3). The ﬂanking regions remain dynamically disordered. (B) Clamp. The Oct-1 transcription factor has a bipartite DNA recognition motif. The two
globular binding domains are connected by a 23 residue long disordered linker (1hf0), shortening of which reduces binding aﬃnity. (C) Flanking. The
p27Kip1 cell-cycle kinase inhibitor binds to the cyclin−Cdk2 complex (1jsu). The kinase binding site is ﬂanked by a∼100 residue long disordered linker,
which enables T187 at the C-terminus to be phosphorylated. (D) Random. UmuD2 is a dimer that is produced from UmuD by RecA-facilitated self-
cleavage (1i4v). The resulting proteins exhibit a random coil signal in circular dichroism experiments at physiologically relevant concentrations.
Mechanistic categories: (E) Conformational selection. The fuzzy N-terminal acidic tail of theMax transcription factor (1nkp) facilitates formation of the
DNA binding helix (dark red) of the leucine zipper basic helix−loop−helix (bHLH) motif. (F) Flexibility modulation. The disordered serine/arginine-
rich region of the Ets-1 transcription factor (1mdm) changes DNA binding aﬃnity by 100−1000-fold by modulating the ﬂexibility of the binding
segment via transient interactions. (G) Competitive binding. The acidic fuzzy C-terminal tail of high-mobility group protein B1 (2gzk) competes with
DNA for the positively charged binding surfaces. (H) Tethering. The binding of the virion protein 16 activation domain to the human transcriptional
coactivator positive cofactor 4 (2phe) is facilitated by acidic disordered regions, which anchor the binding segments.
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the concentrations of the individual proteins238 and the
association rate constants.84 In conformational selection,
addition of binding partners can result in a population shift in
the conformational ensemble of a disordered protein (see
section 4.2) toward the conformation that is most favorable for
binding.119,145,173,175 This mechanism has been observed in both
protein−protein and protein−nucleic acid interactions.173
Evidence for the role of conformational selection in IDP binding
comes, for example, from the interaction between PDEγ and the
α-subunit of transducin,239 which is important in phototransduction.
Figure 12. A portrait gallery of disorder-based complexes. Illustrative examples of various interaction modes of intrinsically disordered proteins are
shown. Protein Data Bank147 identiﬁers for the structures are given in parentheses. (A) MoRFs. Aa, α-MoRF, a complex between the botulinum
neurotoxin (red helix) and its receptor (a blue cloud) (2NM1); Ab, ι-MoRF, a complex between an 18-mer cognate peptide derived from the α1 subunit
of the nicotinic acetylcholine receptor from Torpedo californica (red helix) and α-cobratoxin (a blue cloud) (1LXH). (B) Wrappers. Ba, rat PP1 (blue
cloud) complexed withmouse inhibitor-2 (red helices) (2O8A); Bb, a complex between the paired domain from theDrosophila paired (prd) protein and
DNA (1PDN). (C) Penetrator. Ribosomal protein s12 embedded into the rRNA (1N34). (D) Huggers. Da, E. coli trp repressor dimer (1ZT9); Db,
tetramerization domain of p53 (1PES); Dc, tetramerization domain of p73 (2WQI). (E) Intertwined strings. Ea, dimeric coiled coil, a basic coiled-coil
protein from Eubacterium eligens ATCC 27750 (3HNW); Eb, trimeric coiled coil, salmonella trimeric autotransporter adhesin, SadA (2WPQ); Ec,
tetrameric coiled coil, the virion-associated protein P3 from Caulimovirus (2O1J). (F) Long cylindrical containers. Fa, pentameric coiled coil, side and
top views of the assembly domain of cartilage oligomeric matrix protein (1FBM); Fb, side and top views of the seven-helix coiled coil, engineered version
of the GCN4 leucine zipper (2HY6). (G) Connectors. Ga, human heat shock factor binding protein 1 (3CI9); Gb, the bacterial cell division protein
ZapA from Pseudomonas aeruginosa (1W2E). (H) Armature. Ha, side and top views of the envelope glycoprotein GP2 from Ebola virus (2EBO); Hb,
side and top views of a complex between theN- and C-terminal peptides derived from themembrane fusion protein of the Visna (1JEK). (I) Tweezers or
forceps. A complex between c-Jun, c-Fos, and DNA. Proteins are shown as red helices, whereas DNA is shown as a blue cloud (1FOS). (J) Grabbers.
Structure of the complex between βPIX coiled coil (red helices) and Shank PDZ (blue cloud) (3L4F). (K) Tentacles. Structure of the hexameric
molecular chaperone prefoldin from the archaeumMethanobacterium thermoautotrophicum (1FXK). (L) Pullers. Structure of the ClpB chaperone from
Thermus thermophilus (1QVR). (M) Chameleons. The C-terminal fragment of p53 gains diﬀerent types of secondary structure in complexes with four
diﬀerent binding partners, cyclin A (1H26), sirtuin (1MA3), CBP bromo domain (1JSP), and s100ββ (1DT7). Panels A−M reprinted with permission
from ref 257. Copyright 2011 The Royal Society of Chemistry. (N) Dynamic complexes. Schematic representation of the polyelectrostatic model of the
Sic1−Cdc4 interaction. An IDP (ribbon) interacts with a folded receptor (gray shape) through several distinct binding motifs and an ensemble of
conformations (indicated by four representations of the interaction). The intrinsically disordered protein possesses positive and negative charges
(depicted as blue and red circles, respectively) giving rise to a net charge ql, while the binding site in the receptor (light blue) has a charge qr. The eﬀective
distance ⟨r⟩ is between the binding site and the center of mass of the intrinsically disordered protein. Panel Nwas reprinted with permission from ref 243.
Copyright 2010 John Wiley & Sons, Inc.
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The dynamic ensemble of unbound PDEγ includes a loosely folded
state that resembles its structure when bound to transducin. In
induced folding, a protein undergoes a disorder-to-order
transition upon association with its binding partner.92,146,240
Evidence for this mechanism in IDP binding comes, for example,
from a study investigating the disordered pKID region of CREB
and the KIX domain of CREB-binding protein. Upon binding of
pKID to the KIX domain, an ensemble of transient encounter
complexes forms, which appear to be stabilized primarily by
hydrophobic contacts and evolve to form the fully bound state
via an intermediate state without disassociation of the two
domains.91,241
6.1. Fuzzy Complexes
Although disordered protein regions frequently fold upon
interacting with other proteins, complexes with IDPs often
retain signiﬁcant conformational freedom and can only be
described as structural ensembles.242 The conformations that
disordered proteins adopt in the bound state cover a continuum,
similar to the structural spectrum of free, unbound IDPs,243 and
range from static to dynamic, and from full to segmental
disorder.242 In static disordered complexes, disordered regions
can adopt multiple well-deﬁned conformations in the complex,
whereas in dynamic disorder they ﬂuctuate between various
states of an ensemble in the bound state.
Disorder in the bound state can be classiﬁed into four
molecular modes of action, each of which is associated with
speciﬁc molecular functions (Figure 11A−D).176,242 (i) The
polymorphic model is a form of static disorder, with alternative
bound conformations serving distinct functions by having
diﬀerent eﬀects on the binding partner. Examples are the Tcf4
β-catenin binding domain244 and the WH2 binding domains of
thymosin β4 or ciboulot,245 which have been shown to adopt
several distinct conformations upon β-catenin and actin binding,
respectively. Diﬀerent actin−WH2 domain complexes have
alternative interaction interfaces and result in actin polymers with
diﬀerent topologies.245 The (ii) clamp and (iii) ﬂanking models
represent forms of dynamic disorder in which complex formation
either involves folding upon binding of two disordered segments
that are connected by a linker that remains disordered, or the
reverse situation, respectively. The cyclin-dependent kinase
(Cdk) inhibitor p21, for example, acts as a clamp. It contains a
dynamic helical subdomain that serves as an adaptable linker that
connects two binding domains and enables these to speciﬁcally
bind distinct cyclin and Cdk complex combinations.246 In both
the clamp and the ﬂanking models, disordered regions near the
interacting protein segments (often short peptide motifs)
contribute to binding by inﬂuencing aﬃnity and speciﬁcity.242,247
This phenomenon relates to the importance of the sequence
context in modulating disordered binding elements (see section 3).
Finally, (iv) the random model is an extreme version of dynamic
disorder in protein complexes, which occurs when the IDR
remains largely disordered even in the bound state. In this
case, interaction is achieved via linear motifs that do not get ﬁxed
upon binding. An example is the self-assembly of elastin, where
solid-state NMR has provided evidence for dynamic disorder
within elastin ﬁbers, which exhibit random-coil like chemical shift
values.248 Another case is the complex between the Cdk inhibitor
Sic1 and the SCF ubiquitin ligase subunit Cdc4, which is formed
in a phosphorylation-dependent manner.249 At any given time,
only one out of nine Sic1 phosphorylation sites interact with the
core Cdc4 binding site, while the others contribute to the binding
energy via a secondary binding site or via long-range electrostatic
interactions (Figure 12N). Hence, binding interchanges
dynamically within the Sic1−Cdc4 complex to provide ultraﬁne
tuning of the aﬃnity.249,250
Bound disordered regions can impact the interaction aﬃnity
and speciﬁcity of the complex and tune interactions of folded
regions176 with proteins or DNA.251 Four diﬀerent mechanisms
have been proposed for the formation of fuzzy complexes (Figure
11E−H). (i) The ﬁrst is conformational selection, when the
disordered region shifts the conformational equilibrium of the
binding interface toward the bound form. The fuzzy N-terminal
tail of the Max transcription factor, for example, reduces
electrostatic repulsion in the basic helix−loop−helix (bHLH)
domain and thereby facilitates formation of the DNA recognition
helices, which increases binding aﬃnity by 10−100-fold.252 (ii)
In the second mechanism, the disordered region(s) modulate
ﬂexibility of the binding interface. The serine- and arginine-rich
region of the Ets-1 transcription factor exempliﬁes this
mechanism, which reduces DNA binding aﬃnity by 100−
1000-fold.253 (iii) The third mechanism is competitive binding of
the disordered region. Here, the IDR acts as a competitive
inhibitor of other regions in the same protein for binding to a
partner. The acidic fuzzy C-terminal tail of high-mobility group
protein B1 (HMGB1) negatively regulates interaction of the
HMG DNA binding domains by occluding the basic DNA-
binding surfaces.254 (iv) In the fourth mechanism, the disordered
region serves to tether a weak-aﬃnity binding region to increase
its local concentration. For example, a fuzzy N-terminal domain
anchors the human positive cofactor 4 (PC4) to several
transactivation domains including the herpes simplex virion
protein 16 (VP16).255 All mechanisms of disordered complex
formation aﬀect binding to diﬀerent degrees and can be further
tuned by post-translational modiﬁcations.176,251 PTMs in the
disordered region may act as aﬃnity tuners by modulating the
charge available for biomolecular interactions.256
6.2. Binding Plasticity
Structural analysis of a large number of intrinsic disorder-based
protein complexes resulted in another categorization of IDRs
based on their binding plasticity (Figure 12).257 Examples of
relatively static IDR-based complexes are (i) mono- and
polyvalent complexes, which typically consist of interactions
between disordered segments and one or multiple spatially
distant binding sites on their binding partners, respectively, (ii)
chameleons, such as p53, that have diﬀerent structures when
binding to diﬀerent proteins, (iii) penetrators that bury
signiﬁcant parts of the protein inside their binding partners,
and (iv) huggers, which function in protein oligomerization, for
example, by coupled folding and binding of disordered
monomers. In addition to these relatively static complexes
involving IDRs, one can identify coiled-coil-based complexes.
Regions that make up coiled coils are typically highly disordered
in monomeric state and gain helical structure upon coiled-coil
formation, giving rise to several distinguishable types of
complexes, such as intertwined strings, connectors, armatures,
and tentacles.
7. EVOLUTION
Disordered regions typically evolve faster than structured
domains.51−56,107 This behavior largely stems from a lack of
constraints on maintaining packing interactions, which drives
purifying selection in structured sequences.258 However,
disordered residues do display a wide range of evolutionary
rates (Box 2). The following section discusses the evolutionary
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classiﬁcations of disordered protein regions. IDRs with similar
functions and properties tend to have similar evolutionary
characteristics.
7.1. Sequence Conservation
While the amino acid sequence of disordered regions evolves at
diﬀerent rates, the property of disorder is usually conserved for
functional sequences.54,159 Sequence conservation of IDRs varies
according to their speciﬁc functions and provides another means
for their classiﬁcation.54,259,260 Three biologically distinct classes
of IDRs with speciﬁc function were identiﬁed using a
combination of disorder prediction and multiple sequence
alignment of orthologous groups across 23 species in the yeast
clade (Figure 13): (i) ﬂexible disorder describes regions where
disorder is conserved but that have quickly evolving amino acid
sequences (i.e., there is a requirement to be disordered,
regardless of the exact sequence), (ii) constrained disorder
describes regions of conserved disorder with also highly
conserved amino acid sequences, and (iii) nonconserved
disorder, where not even the property of being disordered is
conserved in closely related species. For ﬂexible disorder, low
sequence conservation is expected if the property of disorder
itself, as opposed to disorder in combination with speciﬁc
sequence, is the only requirement for function. Examples of
functions that mainly require the biophysical ﬂexibility of
disordered regions are entropic springs, spacers, and ﬂexible
linkers between well-folded protein domains.37,39,57,58 The linker
in RPA70 is an example where the dynamic behavior is conserved
even when the sequence conservation is low.60 Flexible disorder
is the most common of the three evolutionary classes with just
over one-half of disordered residues in yeast. It appears to
account not just for the “ﬂexibility” functions mentioned above,
but also for many of the characteristics traditionally associated
with disordered regions, such as strong association with signaling
and regulation processes,35,50,104,190,261,262 rapid sequence
evolution,51−56,107 the presence of short linear motifs (which
are themselves conserved, see below),47,72 and tight regulation
(see section 8).68,263 By contrast, constrained disorder (about a
third of disordered residues in yeast) is associated with diﬀerent
properties and functions, such as chaperone activity and RNA-
binding ribosomal proteins.54 Many proteins that contain the
evolutionarily constrained type of disorder can adopt a ﬁxed
conformation, suggesting that these regions might undergo
folding upon binding to their targets. This structural transition
might impose a high degree of local structural constraints, which
results in constraints on the protein sequence alongside
requirements to be ﬂexible.54 Constrained disordered residues
also occur more often in annotated protein sequence families
(domains) than ﬂexible disorder, but both types are strongly
depleted in domains compared to structured regions. In human,
both ﬂexible and constrained disorder are enriched in proteins
functioning in diﬀerentiation and development,264 which reﬂects
the importance of IDPs in these processes. Finally, nonconserved
disorder accounts for around 17% of disordered residues in yeast
and appears to be largely nonfunctional.
Short linear motifs (see section 3.1)48,125 constitute a special
case. Even though SLiMs almost exclusively lie within disordered
regions, their own amino acid sequence tends to be conserved.48
These properties, together with the diﬃculty of aligning rapidly
evolving disordered sequences, result in the motifs to move
around when comparing their position in diﬀerent sequences. In
fact, not only do motifs move around (due to insertions and
deletions of amino acids around the motif in the sequence67,265),
they can also permute their positions with respect to other
structural and functional modules. For example, SUMO
modiﬁcation sites in p53 are seen after and before the
oligomerization domain in human and ﬂy, respectively.266 Such
behavior could emerge by convergent evolution and loss of the
motif in the original site, as only a few amino acids need tomutate
to make a new motif elsewhere in the sequence. As long as the
position of the motif with respect to the other modules does not
aﬀect function, such permutations will not aﬀect ﬁtness and
hence may emerge relatively easily during evolution. These are
indeed confounding issues when aligning disordered regions
among orthologous proteins to identify functional motifs.
In many ways, the disordered regions that contain SLiMs
constitute ﬂexible disorder as by the above classiﬁcation, as their
main role is to provide ﬂexibility to enable access to the linear
motif for proteins that will bind them as ligands267 or introduce
post-translational modiﬁcations.47,48 Phosphorylation sites are
closely related to short linear motifs that function in binding, but
are often too short and weakly conserved to recognize via
computational means.268 More than 90% of sites phosphorylated
by the yeast Cdk1 are in predicted disordered regions,67 as
consistent with previous studies highlighting the importance of
IDRs as display sites for phosphorylation and other PTMs (see
sections 2.2 and 3.1).45,46 Comparison of the phosphorylation
sites in orthologues of the Cdk1 substrates revealed that the
precise position of most phosphorylation sites is not conserved.
Instead, clusters of sites move around in the alignment of rapidly
evolving disordered regions.69,250,269 Another example of the role
of ﬂexible disorder in signaling and regulation is the yeast serine-
arginine protein kinase Sky1, which regulates proteins involved
in mRNA metabolism and cation homeostasis. The Sky1 C-
terminal loop is intrinsically disordered and contains phospho-
sites that are important for regulating its kinase activity.270
Conservation analysis has shown that the loop is conserved for
disorder but not for sequence.54
The combination of sequence conservation of IDRs and
conservation of their amino acid composition between human
and seven other eukaryotes (chimp, dog, rat, mouse, ﬂy, worm,
and yeast) also identiﬁes functional preferences.260 IDRs with
high residue conservation (HR) are enriched in proteins involved
in transcription regulation and DNA binding. Low residue
conservation in combination with high conservation of the amino
acid type composition (LRHT) of the IDR (i.e., high similarity of
overall amino acid composition between the human IDR and its
orthologs) is often associated with ATPase and nuclease
activities. Finally, IDRs that show neither conservation of
sequence nor conservation of amino acid composition (LRLT)
are abundant in (metal) ion binding proteins.
7.2. Lineage and Species Speciﬁcity
Increasingly complex organisms have higher abundances of
disorder in their proteomes.35,271 An average of 2% of archaeal,
4% of bacterial, and 33% of eukaryotic proteins have been
predicted to contain regions of disorder over 30 residues in
length,35 although there is much variation within king-
doms.272,273 In human, 31% of proteins are more than 35%
unstructured,68 and 44% contain stretches of disorder longer
than 30 residues49,161,208 (similar data shown in Figure 2A).
Human IDPs are spread relatively uniformly across the
chromosomes, with percentages ranging from 38% (for genes
encoding IDPs on chromosome 21) to 50% on chromosomes 12
and X.161 A computational analysis of disorder in prokaryotes has
corroborated the higher abundance of disorder in Bacteria as
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Figure 13. Classiﬁcation of disordered regions according to their evolutionary conservation (constrained, ﬂexible, and nonconserved disorder). (A)
Schematic of computing disorder conservation and amino acid sequence conservation. The alignments are used to calculate the percentage of sequences
in which a residue is disordered and the percentage of sequences in which the amino acid itself is conserved. A residue is considered to be conserved
disordered if the property of disorder is conserved in at least one-half of the species. Similarly, the amino acid type of a residue is considered conserved if
it is present in at least one-half of the species. Disordered residues in which both sequence and disorder are conserved are referred to as constrained
disorder. Disordered residues in which disorder is conserved but not the amino acid sequence are referred to as ﬂexible disorder. Residues that are
disordered in S. cerevisiae but not cases of conserved disorder are referred to as nonconserved disorder. (B) Disorder splits into three distinct
phenomena. Functional enrichment maps of proteins enriched in ﬂexible disorder versus constrained disorder. The area of each rectangle is proportional
to the occurrence of that type of disorder in the alignments. Related gene ontology terms are grouped based on gene overlap. Reprinted with permission
from ref 54. Copyright 2011 Springer Science + Business Media.
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compared to Archaea.274 Moreover, in agreement with the low
abundance of disorder in prokaryotes, none of the 13
mitochondrial-encoded proteins are disordered.161 Systematic
analysis of IDP occurrence in 53 archaeal species showed that
disorder content is highly species-dependent.275 For example,
Thermoproteales and Halobacteria proteomes have 14% and 34%
disordered residues, respectively. Harsh environmental con-
ditions seem to favor higher disorder contents, suggesting that
some of the archaeal IDPs evolved to help accommodate hostile
habitats.276
Structural disorder is more common in viruses than in
prokaryotes.277 The characteristics of IDRs seem well suited for
especially small RNA viruses with extremely compact ge-
nomes.278,279 For example, disordered regions could buﬀer the
deleterious eﬀects of mutations introduced by low-ﬁdelity virus
polymerases better than would structured domains.277 The
ﬂexibility of IDRs to interact with many diﬀerent proteins, such
as proteins of the host immune system, is another useful feature
for compact viruses because it maximizes the amount of
functionality they encode while minimizing the required genetic
information.280 At the same time, several human innate
immunity proteins have predicted disordered regions that
could be important for their pathogen defense function.281 For
example, the RIG-I-like receptors (RLRs) RIG-I and MDA5
recognize diﬀerent types of viral double-stranded RNA
(dsRNA).282 This functional divergence is partly achieved by
diﬀerential ﬂexibility of a loop that is rigid in RIG-I, but
disordered in MDA5, resulting in diﬀerent RNA binding
preferences.283 Furthermore, the disordered linker between the
RNA-binding domains and the two N-terminal CARD (caspase
activation and recruitment) domains of MDA5 helps facilitate
oligomerization of the CARD domains, which initiates down-
stream signaling.283 Activated RIG-I and MDA5 promote the
formation of prion-like aggregates of the CARD domains of
MAVS (mitochondrial antiviral-signaling).284MAVS has a highly
disordered central region that contains multiple phosphorylation
sites and interacts with several proteins, such as TRAF2 and
TRAF6 through their respective consensus binding motifs
(PxQx[TS] and PxExx[FYWHDE], respectively).285 These
interactions are part of a signaling pathway that activates the
transcription factors IRF3/7 and NF-κB, leading to the
expression of proinﬂammatory cytokines such as IFN-α/β and
various proteins with direct antiviral activity.282 For example, to
counteract viral infection, protein kinase R (PKR) phosphor-
ylates the translation initiation factor eIF2α in the presence
dsRNA, which reduces global protein synthesis in the cell.286
PKR contains a long disordered interdomain region that may
become ordered upon RNA binding and could aﬀect PKR
dimerization.287,288 Interestingly, viruses counteract PKR action
bymimicking eIF2α and competing for PKR binding, as has been
shown in the case of the poxvirus protein K3L.289 PKR is under
intense positive selection to keep recognizing eIF2α while
minimizing interaction with viral antagonists.289 Many of the
changing sites in PKR are in a dynamic loop near the interaction
interface with both eIF2α and K3L.290 Similarly, recognition of
retrovirus capsids by the restriction factor TRIM5α is mediated
by disordered regions in the SPRY domain, which bear many
positively selected residues that are essential for the antiviral
activity.291 The SPRY domain exists as an ensemble of disordered
conformations that determine the speciﬁcity and aﬃnity of the
interaction between TRIM5α and the viral capsid.292−294 In this
way, the evolutionary ﬂexibility of disordered regions (see
section 7.1) provides opportunities for proteins of the host
immune system to compete with rapidly changing pathogens
while maintaining their functionality.
In addition to the variation in prevalence of disordered regions
between species, diﬀerent kingdoms of life seem to use conserved
IDRs for diﬀerent functions: eukaryotic and viral proteins use
disorder mainly for mediating transient protein−protein
interactions in signaling and regulation, while prokaryotes use
disorder mainly for longer lasting interactions involved in
complex formation.159 Thus, knowledge on the lineage, species,
and origin of a disordered region could help in predicting its
likely function.
7.3. Evolutionary History and Mechanism of Repeat
Expansion
Tandem repeats are enriched for intrinsic disorder (see
section 5.7), and IDRs are increasingly abundant in increasingly
complex organisms (see section 7.2). The genetic instability of
repetitive genomic regions in combination with the structurally
permissive nature of IDRs might have driven the increase in the
amount of disorder during evolution. Disordered repeat regions
have been shown to fall into three categories, based on their
evolutionary history and acquired functional properties (Figure 14):61
type I regions have not undergone functional diversiﬁcation after
repeat expansion (e.g., the titin PEVK domain), type II repeats
have acquired diverse functions due to mutation or diﬀerential
location within the sequence (e.g., the C-terminal domain of
eukaryotic RNA polymerase II), and type III regions have gained
new functions as a consequence of their expansion per se (e.g.,
the prion protein octarepeat region).
8. REGULATION
Altered availability of IDPs is associated with diseases such as
cancer and neurodegeneration.190,263,295−299 Indeed, genes that
are harmful when overexpressed (i.e., dosage-sensitive genes)
often encode proteins with disordered segments.300 Multiple
mechanisms at diﬀerent stages during gene expression (from
transcript synthesis to protein degradation) control the
availability of IDPs.68 Their tight regulation ensures that IDPs
Figure 14. Repeat expansion creates IDRs. IDRs are abundant in
repeating sequence elements, which suggests that repeat expansion is an
important mechanism by which genetic material encoding for structural
disorder is generated. The expanding repeats may fall into three classes
(types) in terms of their functional diversiﬁcation following expansion.
Individual repeats may remain functionally equivalent (type I), or
diversify (type II), or collectively acquire a completely new function
(type III). Dark-tone red indicates structural disorder of the repeat,
which may undergo full (dark-tone blue) or partial (green) induced
folding upon binding to a partner. Adapted with permission from ref 61.
Copyright 2003 John Wiley & Sons, Inc.
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are available in appropriate levels and for the right amount of
time, thereby minimizing the likelihood of ectopic interactions.
Disease-causing altered availability of IDPs may result in
imbalances in signaling pathways by sequestering proteins
through nonfunctional interactions involving disordered seg-
ments (i.e., molecular titration263). The following section
discusses possible functional roles of proteins with IDRs based
on their cellular regulatory properties such as transcript
abundance, alternative splicing, degradation kinetics, and post-
translational processing.
8.1. Expression Patterns
Five diﬀerent expression patterns were identiﬁed for transcripts
encoding highly disordered proteins by investigating the mRNA
levels from over 70 diﬀerent human tissues and comparing the
number of tissues in which IDP transcripts are expressed against
the level of expression (Figure 15).208 The expression classes are
associated with speciﬁc functions. (i) The ﬁrst subgroup (Figure 15,
light blue markers) shows constitutive high expression in all tissues
and consists exclusively of large ribosomal subunit proteins, which
are almost entirely disordered. (ii) The second group (blue-green)
represents transcripts that showhigh expression levels in themajority
of tissues. These often function as protease inhibitors, splicing factors,
and complex assemblers. (iii) Moderately expressed transcripts
(green) typically encode disordered proteins involved in DNA
binding and transcription regulation. (iv) IDPs that are expressed in a
tissue-speciﬁc manner (yellow) are enriched for cell organization
regulators, transcription cofactors, and factors that promote complex
disassembly. Finally, (v) the remaining transcripts form a group
(gray) not detected to be abundant in any of the tissues studied. This
low and transient expression group contains more than one-half of
the IDP transcripts analyzed and has a variety of functions.
8.2. Alternative Splicing
Trends in transcriptional regulation (alternative promotor and
polyadenylation site usage) and post-transcriptional regulation
(alternative splicing by inclusion or exclusion of exons) can also
be informative of the role that speciﬁc disordered protein regions
play in the cell (Figure 16). Alternatively spliced exons are overall
more likely to encode intrinsically disordered rather than
structured protein segments.161,301−303 This tendency is even
more pronounced in alternative exons whose inclusion or
exclusion is regulated in a tissue-speciﬁcmanner.304 IDRs that are
encoded by these tissue-speciﬁc alternative exons frequently
inﬂuence the choice of protein interaction partners and can be
instrumental in protein regulation304,305 by embedding binding
Figure 15.A summary of expression−function trends for human transcripts encoding highly disordered proteins. The x-axis represents the log10 number
of tissues in which the transcript is expressed; the y-axis represents the log10 average magnitude of expression within the tissues. From the data, ﬁve
distinct functional classes of highly disordered human proteins become apparent. Adapted with permission from ref 208. Copyright 2009 Springer
Science + Business Media.
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motifs, and residues that can be post-translationally modiﬁed.304
However, simple alteration of the length of a disordered region306
can alsomodulate the overall protein function (Figure 16). Changes
in IDR length can be an eﬀective mechanism for modifying
the aﬃnity of interactions that a protein makes, particularly
in instances where a disordered region is responsible for the
positioning of protein binding motifs or domains.307,308
Among the alternative exons, those that exhibit conserved
splicing patterns across diﬀerent species are particularly likely to
have important regulatory roles. For example, tissue-speciﬁc
exons, which are alternatively spliced in multiple diﬀerent
mammals, remarkably often contain IDRs with embedded
phosphosites.309 Disordered regions encoded by these exons
are hence likely to act as modulators of protein function
depending on the tissue where they are expressed.309 While
tissue-speciﬁc exons that are alternatively spliced in a conserved
fashion often code for phosphosites, the emergence of novel
exons in a gene, although at ﬁrst likely detrimental,310 is a
possible template for the evolution of short interaction motifs.311
Furthermore, changes in exon regulation can also be important
for the emergence of novel adaptive functions. Accordingly,
protein segments encoded by exons, which are alternatively
spliced either in a single species or in a whole evolutionary
lineage, are enriched in short binding motifs, and alternative
inclusion of disordered regions encoded by these exons is
conceivably a source of evolutionary novelty.312
In addition to the tendency of cassette alternative exons to
frequently encode IDRs, exons adjacent to the alternatively
spliced ones are also likely to code for disordered regions around
the insertion point for the alternatively spliced segment.264,302
These disordered regions not only provide the structural
ﬂexibility that tolerates both presence and absence of the
alternatively spliced segment, but they can also contain
interaction motifs themselves.264 Furthermore, on the transcrip-
tional level, diversity in protein isoforms can be created through
both alternative splicing and usage of alternative promoters and
polyadenylation sites. Protein segments that are encoded by the
two latter mechanisms can contain disordered regions with
motifs that deﬁne protein localization and stability.313 Taken
together, these examples illustrate how better understanding of
gene regulation and knowledge of evolutionarily conserved and
novel isoforms can provide insights into possible functional roles
of whole proteins and speciﬁc protein regions.
Figure 16. Transcriptional and post-transcriptional gene regulation can be informative of IDR function. How inclusion of exons that code for IDRs is
regulated during gene transcription and alternative splicing can give insights into the functional roles of the encoded disordered regions. For example,
tissue- or developmental-speciﬁc regulation of alternative splicing or alternative promoter and polyadenylation site usage can be associated with
important roles of the encoded IDRs in protein regulation and cellular interactions through, for example, the presence of binding motifs and
phosphosites. Additionally, information on the conservation of patterns of exon inclusion (i.e., events shared among diﬀerent evolutionary lineages
versus species-speciﬁc events) can aid in better characterization of the encoded IDRs. The ﬁgure illustrates a hypothetical example where an exon
(largest red box) that is included in a tissue-speciﬁc manner both in human and in mouse encodes an IDR that embeds a phosphosite (P) and is involved
in protein regulation. The human gene depicted in the ﬁgure has an additional exon (smallest red box), which encodes an IDR with a short interaction
motif and which is also included in a tissue-speciﬁc manner in humans. Gene structures, mature mRNAs, and corresponding protein isoforms are shown
for human and mouse brain and heart tissues. On the right, possible functional roles of the IDRs encoded by the brain isoforms are illustrated. The
examples illustrate how protein functional space can increase due to alternative splicing of exons that encode IDRs. Adapted with permission from ref
304. Copyright 2012 Elsevier.
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8.3. Degradation Kinetics
Another emerging functionality of disordered regions is their role
in protein degradation.314−321 Protein half-life generally
correlates with the fraction of disordered residues,68,317 and
proteins that get ubiquitinated speciﬁcally upon heat shock stress
are typically disordered.322 Although ubiquitination by E3 ligases
has a dominant role in recruiting proteins to the proteasome for
degradation,323,324 some IDRs of suﬃcient length allow for
eﬃcient initiation of degradation by the proteasome independent
of the ubiquitination status. This idea is supported by in vitro
experiments showing that degradation of tightly folded proteins
is accelerated when a disordered region is attached to model
substrates.315,321 Eﬃcient degradation only occurs when the
disordered terminal region is of a certain minimal length,321 and
degradation may be initiated by IDRs either at the protein
terminus or internally.314−321 Proteins that contain IDRs of
suﬃcient length may therefore have increased turnover, although
the exact length requirements will depend on the substrate. At
the same time, not all IDRs inﬂuence protein half-life. For
example, disordered polypeptides with speciﬁc amino acid
compositions such as glycine-alanine and polyglutamine repeats
can attenuate rather than accelerate degradation by the
proteasome.325−327 The formation of protein complexes or
transient interactions with other proteins may also protect IDPs
from degradation. Thus, we can distinguish a novel functional
class of IDRs: those that inﬂuence protein degradation
(degradation accelerators) versus those that do not. These
properties might be associated with speciﬁc protein function. For
example, proteins that contain IDRs of a given length are
probably more susceptible to degradation, possibly linking them
to functions of IDPs with low expression.
Some highly disordered proteins (e.g., p53, p73, IκBα, BimEL)
can, at least in vitro, be degraded by the 20S proteasome
independent of ubiquitination.328−333 Specialized proteins
termed “nannies” have been shown to bind to and protect
IDPs from ubiquitin-independent 20S proteasomal degrada-
tion.334 A free IDP, such as newly synthesized p53, might be
degraded by the 20S proteasome, which leads to fast degradation
kinetics. After a nanny binds the IDP (Hdmx in the case of p53),
slower, ubiquitin-dependent degradation by the 26S proteasome
takes place. This biphasic decay has been proposed as a way to
distinguish structured proteins from IDPs and the proteins that
protect them from degradation.334
8.4. Post-translational Processing and Secretion
The majority of secretory proteins are targeted to the
endoplasmic reticulum (ER) via an N-terminal signal peptide,
which helps to initiate translocation of nascent chains into the
ER.335,336 Bioinformatic analysis of proteins containing N-
terminal ER signal peptides has identiﬁed only 10% of these
proteins as IDPs (>70% disordered), suggesting that IDPs are
under-represented in the secretome.337 The fact that secreted
proteins are rarely IDPs might be partially explained by the
requirement for largely disordered proteins to contain an α-
helical prodomain for correct import into the ER lumen,338 as
demonstrated for intrinsically disordered prohormones.337 IDPs
lacking this structured, α-helical domain were subjected to ER-
associated degradation (ERAD) despite the presence of a signal
peptide.338
Despite the relative depletion of IDPs in the secretome, a
number of important IDPs are processed within the ER,
including many prohormones,337,339 components of the extra-
cellular matrix,340 and proteins involved in biomineralization
(see section 9.3).117,341,342 Pre-pro-opiomelanocortin (pre-
POMC) is a disordered 285 amino acid protein whose signal
peptide is removed during translation to create the 241-residue
pro-opiomelanocortin (POMC). This prohormone has at least
eight putative basic-rich cleavage sites and is able to yield as many
as 10 biologically active peptides including adrenocorticotropic
hormone (ACTH) and β-endorphin. The processing of POMC
is tissue-speciﬁc and depends on the type of convertase enzyme
expressed.343 Other prominent examples of disordered extra-
cellular proteins are elastin and other components of elastic
ﬁbers,344 small integrin-binding ligand N-linked glycoproteins
(SIBLINGs) (see section 9.3),340−342,345 and mucins (see
section 9.2).236 Thus, although secreted proteins are not
particularly enriched for structural disorder overall, some IDPs
are essential for biomineralization, tissue organization, and
hormonal signaling. In line with the features of intracellular IDPs,
extracellular structural disorder is heavily post-translationally
modiﬁed and involved in extensive interactions that organize
large molecular assembles while binding multiple interaction
partners.117,341,342
9. BIOPHYSICAL PROPERTIES
A large range of biophysical work has been carried out on
structural disorder in proteins using a variety of experimental
techniques (Box 2).346 Previous sections have touched on several
aspects. Disordered regions rapidly shift within a continuum of
variably extended or globular conformations and are best
described as dynamic ensembles (see section 4). The amino
acid sequence of a disordered region determines which
conformations it can sample, depending for example on the
charge properties (see section 5.1). Disordered proteins
frequently fold upon binding, and their binding thermodynamics
allow for fast, transient, but highly speciﬁc interactions (see
sections 2, 3, and 6). The following section discusses three other
physical properties that are essential for the biology of some
IDRs and IDPs: solubility, the ability to undergo phase
transitions, and the role in biomineralization.
9.1. Solubility
The solubility of a protein depends upon the favorability of its
interactions with water. Globular proteins bury hydrophobic
amino acids within their solvent-excluded cores, while their
surfaces are generally enriched in polar and charged amino acids
that interact favorably with water, leading to aqueous
solubility.347,348 The presence of hydrophobic surface residues,
for example, binding sites for other proteins, and the
denaturation of otherwise folded proteins lead to the exposure
of hydrophobic residues to water and reduce solubility,
sometimes leading to aggregation and precipitation. Disordered
proteins do not spontaneously fold into globular structures
because their sequences are depleted in hydrophobic amino acids
that, in globular proteins, drive folding (see section 5).31,44 The
accompanying enrichment in polar and charged amino acids, as a
general rule, causes disordered proteins to be soluble in aqueous
solutions. In addition, IDPs are generally resistant to heat-
induced aggregation and precipitation, because disordered
proteins, in isolation, lack extensive secondary and tertiary
structure that in folded, globular proteins is subject to thermal
denaturation. Heat-stability was observed for some of the earliest
examples of IDPs. For example, the highly disordered cyclin-
dependent kinase (Cdk) inhibitor p21 remains soluble and
structurally unaltered from 5 to 90 °C.28 In fact, the related Cdk
inhibitor p27 was puriﬁed by boiling, although at that time it was
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not known to be a disordered protein.349 In that study, boiling
was used as a means to release p27 from its highly stable
complexes with Cdks and cyclins, which, because they are folded
proteins, underwent thermal denaturation and precipitated while
heat-stable p27 remained soluble. This heat-treated preparation
of p27 was subsequently demonstrated to potently inhibit Cdk2-
cyclin A.349
Sequence analysis algorithms have predicted a high prevalence
of IDRs and IDPs in sequenced genomes (see section 7.2).35,271
To experimentally address the issue of the disordered protein
content of a proteome, Galea and co-workers209 treated the
soluble extract of mouse embryo ﬁbroblast cells with heat to
precipitate folded proteins and then used large-scale liquid
chromatography and mass spectrometry methods to identify
∼1300 proteins that remained soluble. Disorder predictions
showed that more than two-thirds of these thermostable proteins
are substantially disordered. This demonstrates that disordered
proteins, as a structural class, are more heat stable and soluble
than their folded counterparts, consistent with their sequence
features and the principles of amino acid solubility. However,
disordered proteins exhibit varying degrees of compaction, which
is inﬂuenced by the presence and patterning of charged residues
within the polypeptide chain (see section 5.1).166−168,196 While
the inﬂuence of compaction on disordered protein solubility has
not been addressed, it is reasonable to expect that the extent of
compaction will inﬂuence the exposure of solubility-promoting
amino acids for interactions with water and therefore aqueous
protein solubility.
It is possible that solubility has inﬂuenced the evolution of
disordered protein sequences, with low abundance disordered
proteins involved in signaling and regulation being less
dependent on high solubility than other disordered proteins
that are highly abundant in certain cell types (e.g., titin in muscle
cells). Several extracellular IDPs use their solubility to great eﬀect
in the sequestration of inorganic molecules in the extracellular
environment (see section 9.3). Apart from evolutionary
considerations, there are practical applications of the high
solubility associated with some disordered protein sequences.
For example, proteins with higher degrees of disorder have an
increased success rate of expression in a cell-free protein
synthesis system.350 Furthermore, Dunker and co-workers
demonstrated that fusion of a variety of disordered polypeptide
tags containing repetitive, highly negatively charged sequences
(termed “entropic bristles”) enhanced the aqueous solubility of
many proteins previously shown to be poorly soluble upon
expression in E. coli.351 Whether the solubilizing eﬀect of these
disordered tags is simply due to an increase in the fraction of
solubility-promoting amino acids or to other eﬀects, such as a
potential molecular chaperone function, has not been
determined. Clearly, however, disordered regions within multi-
domain proteins that also contain folded domains are likely to
inﬂuence overall protein solubility.
9.2. Phase Transition
The involvement of IDRs in phase transitions provides another
biophysical angle to the characterization of proteins that harbor
disordered regions.99 Li and co-workers137 observed that
interactions between recombinant proteins that contain multiple
Figure 17. Involvement of IDRs in phase transitions. (A) Interactions between proteins that contain multiple copies of a speciﬁc domain (an SH3
domain in the ﬁgure) and IDRs withmultiple instances of its interactionmotif (proline-rich SH3motif here) can, at appropriate concentrations, produce
sharp liquid−liquid-demixing phase separations. This phase transition is likely to increase local “active” protein concentrations exploitable for signaling
switches. (B) High concentrations of low-complexity IDRs found in certain RNA binding domains lead to a reversible phase transition with the
formation of highly dynamic hydrogels. These RNA granule-like assemblies consist of heteromeric protein aggregates and allow localization and storage
of functionally related but nonidentical RNA molecules. Adapted from ref 100. Copyright 2013 the Biochemical Society.
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copies of an SH3 domain and IDRs with multiple instances of the
proline-rich SH3 interaction motif (see section 3.1) produced
sharp liquid−liquid-demixing (phase separations) that resulted
in micrometer-sized liquid protein-based droplets (Figure 17A).
The concentrations needed for the phase transition depend on
the valency (i.e., number of repeating units) of the interacting
elements. Importantly, experiments with the natural NCK−
nephrin−N-WASP (neuronal Wiskott−Aldrich syndrome pro-
tein) complex, which contains multiple copies of the same SH3
interaction partners, showed the formation of similar dynamic
droplets, which lead to a signiﬁcant increase in the activity of the
actin nucleation factor Arp2/3.137 The formation of the droplets
is controlled by the degree of phosphorylation of one of the
interaction partners, which potentially explains how the phase
transitions may be regulated in the cell.
A related phenomenon occurs with RNA-binding proteins that
contain IDRs of low sequence complexity. Such regions have
been associated with the regulated formation of cellular RNA
granules.352 Various types of RNA granules are used to modulate
the fate of speciﬁc mRNAs, but their assembly mechanism has
remained unclear. Kato and co-workers353 reconstituted granule-
like RNA assemblies in vitro by exploiting low complexity IDRs.
They demonstrated that the low-complexity IDRs of certain
RNA-binding proteins were necessary for the formation of
granule-like assemblies and that high concentrations of these
regions lead to a reversible phase transition with a highly dynamic
hydrogel state (Figure 17B). Interestingly, hydrogels formed by
the low-complexity IDR of one puriﬁed member of the granules
are capable of binding IDRs of other members and thereby
enable the assembly of heterogeneous macromolecular struc-
tures.353 Many IDRs that can form such functional aggregates
have been shown to be under tight regulation to modulate their
availability in the cell.224 Regulation of IDR abundance can shift
the equilibrium between the monomeric and oligomeric/
aggregate form, thereby preventing formation of undesirable
aggregates and keeping functional assemblies under control.224
Together, these ﬁndings indicate that the biophysical properties
of certain IDRs (such as those that contain speciﬁc low-
complexity regions or linear motifs) enable phase transitions that
are likely to be exploited in various macromolecular assemblies
and could function to bridge the length scale of proteins with that
of organelles.354
Disorder-mediated phase transitions also occur extracellularly,
as exempliﬁed by the mucin family of proteins. These proteins
rely on structural disorder for the formation of gel-like networks
of mucus, which function in the protection of epithelial surfaces
such as those in the airway and the gut.355,356 Extensive
glycosylation of very large disordered regions that are rich in
proline, threonine, and serine residues contributes to the
formation of these structures.357 Mucin-1 can contain up to
120 such repeats, depending on the genetic variant an individual
carries.358 Regulated order-to-disorder transitions ofMucin-2 are
important in the formation of colon mucus aggregates.88,236,359
Mucin-2 trimers are compact structures under the conditions of
the secretory pathway, where the pH is low and calcium is
present, but these structures partially unfold and greatly expand
in more basic environments, such as in the colon, triggering a
phase transition into a mucus polymer gel.88,236,359
9.3. Biomineralization
Most animals are able to produce hard tissues for various
physiological purposes by mineralization of the extracellular
matrix.360,361 Bone and teeth, for example, consist of collagen and
other proteins in conjunction with inorganic calcium phosphate
in the form of hydroxyapatite (HA).360,362 Proteins involved in
hard tissue mineralization are predicted to have very high levels
of disorder,340−342 and disordered proteins are important in
mineral homeostasis in general,117 indicating an important role
for IDRs in these processes. For example, unfolded phospho-
proteins sequester calcium phosphate by forming stable
complexes in which the phosphorylated side-chains of the
proteins occupy the phosphate positions on the surfaces of
calcium phosphate nanoclusters.117 The disordered nature of
these proteins allows them to readily adjust their shapes to
surround and solubilize clusters of calcium phosphate. In this
manner, proteins such as the milk caseins achieve high
concentrations of calcium and phosphate while preventing the
precipitation of the corresponding salts (i.e., calciﬁcation).117
Caseins belong to the highly disordered secretory calcium-
binding phosphoprotein (SCPP) gene family,341 which includes
bone, tooth, milk, and salivary proteins.363
Humans encode ﬁve small integrin-binding ligand N-linked
glycoproteins (SIBLINGs), which are a subset of SCPPs
involved speciﬁcally in regulating bone and teeth formation by
bringing together hydroxyapatite, cell-surface integrins, and
collagens.345,360 These are osteopontin (OPN, or bone
sialoprotein 1), bone sialoprotein 2 (IBSP), dentin matrix acidic
phosphoprotein 1 (DMP1), matrix extracellular phosphoglyco-
protein (MEPE), and dentin sialophosphoprotein (DSPP).235
SIBLINGs are highly disordered340−342,345 and undergo
extensive phosphorylation in the Golgi before they are secreted,
as demonstrated in the case of DSPP, which has approximately
200 phosphoserines.235 DSPP has a particularly extreme serine
and aspartic acid content, and its maturation product dentin
phosphoprotein (DPP, or phosphophoryn) is likely to be one of
the most acidic natural proteins known.
10. DISCUSSION
To get closer to a full understanding of living cells, we need to
know the function of each of their elements. The human genome
project and the many sequencing projects since have helped
reveal the number and makeup of the genes. Experimental
research focused on understanding how individual proteins work
on the molecular level has enabled enormous progress in our
understanding of the workings of proteins in general and of the
systems they work in. However, the majority of studies
investigate a minority of individual proteins, which are
interesting for a variety of reasons, such as their relevance for
disease or because they are classical study objects. Thus, many
genes and the proteins they encode have not been studied in
detail and still have unknown function.
It is likely that many of the functionally uncharacterized
proteins will be similar to already characterized ones.8−10 This
notion forms the basis for computational methods that aim to
improve annotation coverage by predicting the function of novel
and undeﬁned proteins based on information from better-
studied proteins. Databases such as Pfam22 and SCOP24 attest to
the success of these approaches. However, existing methods are
focused primarily on sequences that give rise to well-folded
protein structures and domains. As a result, it is much harder to
gain insight into the function of intrinsically disordered regions
(IDRs) and proteins (IDPs), despite the increasing evidence
of their prevalence and importance for protein functionality
(Figure 1).50 Many important disease proteins such as p53, Myc,
α-synuclein, and BRCA1 are highly disordered, underscoring the
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importance of disordered regions for understanding the
molecular basis of human diseases.263,295,299
In this Review, we have assembled an overview of the major
approaches used to classify and categorize IDRs and IDPs (Table 1).
These classiﬁcation schemes help us understand how disordered
protein functionality is deﬁned and could be used to enhance
function prediction for disordered protein regions in general. In
these ﬁnal sections, we discuss the resources that are currently
available for gaining insight into IDR function (Table 2), we
address potential areas for improvement of the current
approaches, and we propose that combinations of multiple
existing classiﬁcation schemes could achieve higher-quality
function prediction for IDRs. Finally, we suggest areas where
increased eﬀorts are likely to advance our understanding of the
functions of structural disorder in proteins.
10.1. Current Methods for Function Prediction of IDRs and
IDPs
Whichmethods and resources can a researcher use to gain insight
into the functions of the disordered regions in a protein? Current
approaches (Table 2) are mainly based on the presence of
functional features such as short linear motifs (SLiMs), post-
translational modiﬁcation (PTM) sites, molecular recognition
features (MoRFs), and intrinsically disordered domains (IDDs)
(see section 3). These aspects have the potential to shed light on
which interaction partners an IDR may have and how many, as
well as the mode of binding.
10.1.1. LinearMotif-Based Approaches.Mapping of well-
characterized linear motifs onto other protein sequences holds
particular promise for discovering novel functionality. For
example, proteomic characterization of the motif (RxxPDG)
that recruits Tankyrase ADP-ribose polymerases has led to the
identiﬁcation of novel Tankyrase substrates and explains the
basis for mutations causing cherubism disease.364 Similarly,
proteome-wide searches for the SxIP motif have resulted in the
identiﬁcation of previously uncharacterized microtubule plus-
end tracking proteins.365 However, these types of individual
studies require considerable resources.
MiniMotif126 and ELM125 are two major eﬀorts aimed at the
annotation of known instances of linear motifs, which are
primarily found in IDRs, and their binding partners. The
MiniMotif and ELM databases aim to categorize linear motifs of
all functions based on in-depth manual annotation of
experimentally validated instances from the literature. Similar
approaches have also been taken speciﬁcally for PTM site motifs
(see section 10.1.2). Although these resources are excellent
repositories of the functional sites that occur in IDRs, they do
have certain shortcomings. For example, the annotations from
MiniMotif are not publicly available. Although the ELM database
is the most comprehensive database of functional features within
IDRs, at present it does not have the resources to annotate all
motifs in the literature; ELM contains ∼200 classes of linear
motifs with over 2400 instances, but more than 250 classes await
annotation with this number constantly increasing.125 This has
meant ELM is limited to annotating (a fraction) of the shorter
motif classes and does not explicitly consider the longer binding
modules in disordered regions.
Complementary to the annotation eﬀorts, the linear motif
resources employ prediction methods that map functionality
onto regions of proteins with unknown function (i.e.,
unannotated regions). For example, MiniMotif and ELM use
regular expressions derived from experimentally validated and
curated motif instances to search protein sequences. These
searches bring up functional descriptions of sequence instances
that match the regular expressions. A major problem in the
computational detection of short motifs in particular is the high
false positive rate, which means that it is very diﬃcult for users to
identify the instances that are most likely to be functional from
the large total of mostly nonfunctional motif instances that result
from these searches. To overcome this issue, both databases have
Table 2. Current Methods for Function Prediction of Intrinsically Disordered Regions and Proteins
basis for method description method Web site
linear motifs annotation of well-characterized linear motifs, which can be
mapped onto other protein sequences
ELM125 http://elm.eu.org/
MiniMotif126 http://mnm.engr.uconn.edu/
identiﬁcation of putative uncharacterized motifs in protein
sequences
SLiMPrints372 http://bioware.ucd.ie/slimprints.html
phylo-HMM373 http://www.moseslab.csb.utoronto.ca/phylo_HMM/
DiliMot374 http://dilimot.russelllab.org/
SLiMFinder375 http://bioware.ucd.ie/slimﬁnder.html
PTM sites resources of experimentally veriﬁed PTM sites, mostly
phosphorylation
Phospho.ELM268 http://phospho.elm.eu.org/
PhosphoSite376 http://www.phosphosite.org/
PHOSIDA377 http://www.phosida.com/
identiﬁcation and collection of peptide motifs that direct post-
translational modiﬁcations
ScanSite380 http://scansite.mit.edu/
NetPhorest381 http://netphorest.info/
NetworKIN382 http://networkin.info/
PhosphoNET383 http://www.phosphonet.ca/
molecular
recognition
features
collection of veriﬁed sequence elements that undergo coupled
folding and binding
IDEAL388 http://www.ideal.force.cs.is.nagoya-u.ac.jp/IDEAL/
prediction of sequences that undergo disorder-to-order
transitions
MoRFpred385 http://biomine.ece.ualberta.ca/MoRFpred/
ANCHOR386 http://anchor.enzim.hu/
intrinsically
disordered
domains
annotation of disordered protein domains, which can be
detected by sequence proﬁles
Pfam22 http://pfam.sanger.ac.uk/
other prediction of gene ontology functions using protein sequence
features such as intrinsic disorder
FFPred391 http://bioinf.cs.ucl.ac.uk/psipred/
function annotation of experimentally veriﬁed disordered
protein regions
DisProt203 http://www.disprot.org/
predictions of disordered regions combined with information
on MoRFs, PTM sites, and domains
D2P2 49 http://d2p2.pro/
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developed additional methods to improve prediction accuracy
that rely on the use of additional context information, such as
accessibility (using structural models366 and predictions of
intrinsic disorder72), evolutionary conservation,367,368 cell
compartment (based on annotation),126,369 and protein−protein
interactions.128,370,371 These eﬀorts will need to be combined in
the future with a clearer user interface so researchers can more
easily identify the most relevant instances.
De novo predictors make up the ﬁnal category of motif
resources. These predictors computationally identify putative
uncharacterized motifs in protein sequences. There are two
broad types: predictors that identify clusters of amino acids that
are more conserved than surrounding residues (e.g., SLiM-
Prints372 and phylo-HMM373) or those that ﬁnd short peptide
patterns that are over-represented in a set of sequences (e.g.,
DiliMot374 and SLiMFinder375). Although both approaches have
been combined with the gene ontology terms of the identiﬁed
proteins, further development is required to deﬁne potential
functionality.
10.1.2. PTM Site-Based Approaches. In terms of PTM
sites within disordered regions, resources such as Phos-
pho.ELM,268 PhosphoSite,376 and PHOSIDA377 curate exper-
imentally veriﬁed phosphorylation sites and sometimes other
types of modiﬁcations from the literature and genome-scale
studies. Integration of such information with data on SNPs that
are seen in natural populations or in cancer genomes can provide
important insights into the functionality of a PTM site.378,379
Important progress has been made in identifying and cataloging
peptide motifs that direct post-translational modiﬁcations.
ScanSite primarily identiﬁes linear motifs that are likely to be
phosphorylated and play key roles in signaling, such as the SH2
and 14−3−3 motifs.380 Annotation of these sequence motifs is
based on results from binding experiments with peptide libraries
and phage display experiments.380 NetPhorest contains con-
sensus sequence motifs of 179 kinases and 104 phosphorylation-
dependent binding domains.381 In addition, approaches such as
NetworKIN370 systematically integrate experimentally derived
PTM sites with evolutionary information, and deﬁne motifs
around the PTM sites that may be recognized by the kinase. In
this manner, site-speciﬁc interactions between 123 kinases and
speciﬁc PTM sites (often in disordered regions) in 5515
phosphoproteins are predicted.382 Another resource, Phospho-
NET, provides predictions of potential kinases for over 650 000
putative phosphosites.383 Extending these approaches to other
post-translational modiﬁcations is an area of intense research,
and a number of such PTM site prediction programs currently
exist,384 although linking the PTM sites to the modifying
enzymes remains to be addressed for the other types of
modiﬁcations.
10.1.3. Molecular Recognition Feature-Based Ap-
proaches. Two important methods exist for identifying novel
binding modules in IDRs based on the concept of molecular
recognition features (MoRFs). MoRFpred predicts sequences
that undergo disorder-to-order transitions of all types of MoRFs
(α, β, coil, and complex) using a combination of sequence
alignment andmachine learning predictions based on amino acid
properties, predicted disorder, B-factors, and solvent accessi-
bility.385 ANCHOR also predicts parts of disordered regions that
are likely to fold upon binding with their interactors, but does so
by identifying segments that cannot form enough favorable
intrachain interactions to fold on their own and are likely to gain
stabilizing energy by interacting with a globular partner
protein.386,387
An important shortcoming of the MoRF predictions is the
diﬃcultly in identifying which of the binding sites are relevant
and what their functionality might be. This is primarily because
the results are not linked to known MoRF instances with
annotated functions, as is the case for linear motifs, and no clues
are provided regarding the potential role of a binding site or its
interacting partners. The IDEAL database388 collects veriﬁed
elements in disordered regions that undergo coupled folding and
binding upon interaction (Box 1). The careful annotation of well-
described MoRFs in terms of their sequence propensities or
interaction interfaces as well as their known binding partners, and
integration of these annotations with MoRF predictions, would
likely improve the use of these predictions for gaining insight into
IDR functionality.
10.1.4. Intrinsically Disordered Domain-Based Ap-
proaches. Few attempts have been made to systematically
annotate protein domains that are largely made up of intrinsic
disorder. Pfam22 models are able to predict several intrinsically
disordered domains (e.g., KID,WH2, RPEL, and BH3 domains).
However, this seems to be a simple consequence of the fact that
these disordered domains can be described and detected by
sequence proﬁles, rather than an eﬀort directed at annotating
long IDRs. ELM125 has also annotated a small number of long
disordered domains, such as the WH2 motif; however, the main
focus of the database remains on short motifs. Finally, some of
the IDRs that are present in annotated domains are in fact
MoRFs or linear motifs, and linear motifs also frequently fold
upon binding like MoRFs, underscoring the underlying
connections between linear motifs, MoRFs, and IDDs as
functional elements (see section 3.4).
10.1.5. Other Approaches. Only a few IDR classiﬁcations
that are not based on linear motifs, MoRFs, or IDDs have so far
been exploited for function prediction. FFPred is a correlation-
based approach that uses the length and position of IDRs along a
sequence (see sections 5.5 and 5.6), among other general protein
features, to predict the function of the protein in terms of gene
ontology categories (molecular activities and biological
processes).211,389−391 The DisProt database of protein disor-
der203 (Box 1) lists functions of individual disordered regions,
when known from experiments, the major limitation here being
the small number of regions for which exact function has been
characterized. The Database of Disordered Protein Prediction
(D2P2)49 (Box 1) stores predictions of IDRs in whole genomes,
which together with information on MoRFs, PTM sites, and
domains can be used to obtain insight into the possible function
of the IDR and the protein containing it.
10.2. Requirement for Annotation
Future eﬀort in the classiﬁcation of IDRs and IDPs must be
directed at annotation. Substantiating classes with more
examples will lead to reﬁnement of their function descriptions
and will likely reveal inaccuracies in existing classiﬁcation
schemes. For example, there are only a limited number of well-
characterized examples of proteins that contain the evolutionarily
ﬂexible (e.g., RPA70 and Sky1) or constrained types of disorder
(Rpl5 and Hsp90). The same is true for the diﬀerent classes of
dynamic disorder in protein complexes, although eﬀorts are
ongoing there.176 In terms of the functional features of IDRs,
there is a need for annotating MoRFs and longer disordered
binding regions as described in the previous section. Eﬀorts
directed at short linear motifs have been very successful, but only
a small fraction of the potentially thousands of motifs392 have
been annotated. Pfam contains almost 15 000 curated protein
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families,22 while ELM contains less than 200 motif classes,125
suggesting that signiﬁcant numbers of functional features are still
to be identiﬁed and further annotation is required. High-quality
resources that collect all of the experimentally validated
functional regions of intrinsically disordered regions will provide
a strong basis to map functional features onto novel proteins of
unknown function.
10.3. Integration of Methods for Finding IDR and IDP
Function
The current methods for ﬁnding and classifying IDR and IDP
function have been successful in the area of their focus. However,
not all functional characteristics of disordered regions have been
fully exploited, and neither is there a resource that brings all of
these aspects together. The combination of multiple catego-
rizations and features of IDRs is likely to provide a better
understanding of the functionalities encoded in these regions.
A comprehensive IDR function resource should have several
aspects. It starts with a reliable consensus disorder prediction for
the protein sequence of interest (Box 3), such as available in the
D2P2 database (Box 1).49 Functional features, such as SLiMs (see
section 3.1), MoRFs (see section 3.2), and disordered domains
(see section 3.3), can then bemapped on every disordered part of
the protein. The disorder proﬁle allows for the identiﬁcation of
individual IDRs in the protein, as well as the calculation of
disorder properties of the whole protein, such as which disorder
predictors support which IDRs (see section 5.2), the overall
degree of disorder (see section 5.4), the length of the individual
disordered regions (see section 5.5), or the amount of disorder at
the termini (see section 5.6). These can be used to assign general
function to the proteins, such as gene ontology terms that
correlate with these properties. Patterns in amino acid sequence
could reveal additional function. For example, the presence of
tandem repeats or enrichment in certain amino acids (see
sections 5.7 and 7.3) may point toward involvement in certain
processes. The overall sequence composition and the distribu-
tion of charges (see section 5.1) could indicate the solubility of a
polypeptide chain (see section 9.1) and conformational
properties such as the degree of compaction (see section 4).
The combination of sequence complexity and disorder
propensity could suggest function as well (see section 5.3).
Integration of other types of information will determine what
classiﬁcations can additionally be used. Addition of domain
information, such as Pfam, can provide insight into the role of
disordered segments that are commonly associated with speciﬁc
structured domains (see section 3.3). Protein−protein inter-
actions and structures of protein complexes could indicate
interacting partners of IDR binding elements and the mode of
interaction (see section 6). Information about sequence
conservation (see section 7.1) is another important aspect and
could provide clues about evolutionarily constrained or ﬂexible
types of disorder, which are implicated in diﬀerent types of
functions. Knowledge on the origin of a disordered region in
evolution or the species containing the protein sequence of
interest suggests possible functions as well (see section 7.2).
Furthermore, data describing regulatory properties such as gene
expression levels (see section 8.1), alternative splicing (see
section 8.2), and degradation kinetics (see section 8.3) could
implicate IDRs in regulating protein availability and may suggest
or reject roles as interactions hubs, for example. Finally,
biophysical properties of the protein, such as the potential of
multivalent elements to undergo phase transitions (see section 9.2)
and occurrence inside or outside the cell (see sections 8.4 and 9.3),
may suggest involvement in the spatiotemporal organization of
(extra)cellular assemblies.
The hypothetical resource might be able to suggest function
for some of the following examples, although it is clear that in
other cases the biology will be too complicated and the outlook
of function prediction as described here will be unrealistic.
Therefore, the following examples should at this point be
considered as speculative. A long (more than 30 residues) IDR
that shows signs of evolutionarily ﬂexible disorder and contains
no short motifs or other predicted binding regions could be a
ﬂexible linker between domains or an entropic chain. A region
containing a PxxPx[KR] motif ﬂanked by evolutionarily ﬂexible
disorder that is likely to retain an open conformation in the
unbound form (based on the primary structure) probably binds a
class II SH3 domain, and might be involved in transcription
processes if the IDR constitutes the C-terminus of a protein with
an otherwise small degree of disorder. Long IDRs that are
encoded by alternatively spliced exons and have several
nonoverlapping functional motifs and MoRFs might be part of
signaling hubs or assemble multiprotein complexes, the type of
which might be inferred from the combination of binding sites
present. A constitutively expressed, largely disordered IDP with
an amino acid composition promoting intrinsic coil conforma-
tions and conservation of both primary and disorder sequence is
likely to be a ribosomal protein or part of another rigid
multisubunit complex.
It is clear that some classiﬁcations will provide more useful and
direct information about function than others. Some classi-
ﬁcations have been proposed to contrast IDPs with structured
proteins, which does not necessarily make them useful for a
detailed description of disorder function per se. Others have
limited use for prediction because they are conceptual only, or
because of overlap in the properties they describe with other
schemes. Moreover, not all approaches can realistically be
incorporated in a tool. Binding functionality and sequence-based
predictions will generally be possible, but predictions based on
other types of data may be harder. For example, assignment of
evolutionarily constrained or ﬂexible disorder requires automatic
alignment of amino acid and disorder sequences, while gene
expression subtypes can be derived from the wealth of microarray
and RNA sequencing data. Various types of information are
already brought together in the D2P2 database,49 which contains
information on disordered regions, MoRFs, PTM sites, and
structured domains, and in ELM,125 which shows information on
linear motifs, disorder, phosphorylation, domains, protein−
protein interactions, and secondary structure. Further extension
of resources like these, with information on both structured and
disordered regions, holds great promise toward creating a
comprehensive overview of the functional elements and
properties of a protein.
10.4. Future Directions
A major area of improvement in the description of disordered
protein regions pertains to their dynamic behavior.172,178 IDRs
ﬂuctuate rapidly over an ensemble of heterogeneous con-
formations (see section 4.2), the relative free energies and
propensities of which are determined by the amino acid sequence
(see section 5.1). The relationship between sequence and
structural ensemble is important because it describes what part of
the time the chain is in a compact state, and what part of the time
it is more accessible. Knowledge about these structural subtypes
and about how sequence contexts and chemical modiﬁcations of
the chain (e.g., by PTMs) modulate the structural ensemble is
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vital for the correct description of IDR behavior and has direct
implications for the functional roles such regions can have in the
cell.157
Classical methods are not optimally designed to take structural
dynamics into account. For example, current disorder prediction
technology is successful at distinguishing sequence stretches that
are likely to be disordered versus those that are likely to be part of
autonomously folded domains, resulting in a binary verdict
(disordered versus structured) within a certain conﬁdence limit
(Box 3). Although predicted disordered regions correlate well
with experimentally determined backbone dynamics,393 detailed
prediction of conformational subtypes requires a more
sophisticated description of disorder. A recent method for the
prediction of protein backbone dynamics, trained based on order
parameters estimated from experimental chemical shifts, is not
only capable of distinguishing diﬀerent structural organizations
with varying degrees of ﬂexibility, such as folded domains,
disordered linkers, molten globules, andMoRFs, but regions that
are predicted to be dynamic also correspond well with
conventional predictions of IDRs.394 Furthermore, high-
throughput atomistic simulations of sequence ensembles can
provide information about the degree of conformational
heterogeneity,395 which can be quantiﬁed by various parameters,
such as an information theory measure396 or an order parameter-
like measure.397 One could imagine a multiple-component
scheme describing structural and dynamic characteristics that
would assign, for example, residues in a random coil small values
for the fractional population of secondary structure, a large value
for spatial ﬂuctuations, a fast interconversion rate, and large
values for structural heterogeneity. Conversely, molten globule
residues would be assigned a relatively large value for the
fractional population of secondary structure, a smaller value for
spatial ﬂuctuations and structural heterogeneity, and a slower
interconversion rate. Progress in the objective description of
conformational ensembles will likely require development of
novel structural classiﬁcations. Such eﬀorts will be greatly
encouraged by the new pE-DB database of structural ensembles
(Box 1).398 There is considerable room for growth at the
interface between atomistic simulations, physical theories,
machine learning methods, and experiments, to enable the
unmasking of the connection between disorder dynamics and
molecular and system level functions of IDRs and IDPs.
Full understanding of the cellular functions of IDPs will also
require knowledge of their abundance, their interactions, and
their physical state in the physiological context. Are IDPs always
bound to target proteins, are they chaperoned, or are there pools
of unbound IDPs? Answers to these questions will vary among
diﬀerent IDPs and will depend on the exact context in the cell.
However, the discovery of features that can help classify and
categorize IDRs in terms of their cellular status will lead to more
insights into their function. For example, entropic chains may
mostly be disordered even in the cell, whereas eﬀectors and
assemblers may mostly be associated with other proteins in
folded conformations and exchange binding partners by
competition rather than by dissociation to the free, disordered
state. Scavengers likely populate both disordered and ordered
states, depending on whether or not their ligand is bound. Thus,
investigations of the in-cell status of IDPs399 will be crucial
toward understanding their biological roles.
11. CONCLUSION
The functional versatility of intrinsically disordered regions in
proteins is remarkable. Our hope is that the overview of diﬀerent
groups, categories, types, and classes of IDRs and IDPs provided
in this Review can serve as a basis for understanding how this
functional versatility is achieved and that it oﬀers novel ways of
Box 1. Databases of Intrinsically Disordered Regions and
Proteins
Several resources exist that collect experimental or computa-
tional information on disordered regions in proteins. The
Database of Protein Disorder (DisProt, http://www.disprot.
org/) was developed to facilitate research on protein disorder by
organizing the rapidly increasing knowledge about the
experimental characterization and the functionalities of IDRs
and IDPs.203,400 The database includes the location of the
experimentally determined disordered region(s) in a protein
and the methods used for disorder characterization. Addition-
ally, where known, entries list the biological function of an IDR
and how it performs this function. As of the latest release (6.02,
May 24, 2013), DisProt contained 694 IDP entries and 1 539
IDRs.
The IDEAL database (http://www.ideal.force.cs.is.nagoya-u.
ac.jp/IDEAL/) also collects annotations of experimentally
veriﬁed IDPs.388 This database focuses on regions that undergo
coupled folding and binding upon interaction with other
proteins (regions for which there is evidence for both a
disordered isolated state and an ordered bound state), such as
MoRFs and certain linear motifs (see section 3). It also suggests
putative sequences for which there is only evidence of an
ordered bound state, but that are thought to undergo induced
folding based on, for example, the presence of a veriﬁed folding-
upon-binding element in a homologue. The latest version (30
August 2013) contained 340 proteins with annotated IDRs of
which 148 contain veriﬁed or putative elements that undergo
folding upon binding.
MobiDB (http://mobidb.bio.unipd.it/) collects experimen-
tal data on IDRs from DisProt,203 IDEAL,388 and the Protein
Data Bank147 (missing residues in crystal structures and
structurally mobile regions in NMR ensembles).401 It also
stores disorder prediction data from three methods. The total of
disorder information is summarized in a weighted consensus.
The latest version (1.2.1, August 28, 2012) contained 26 933
proteins for which there is experimental data on the presence or
absence of disorder and disorder predictions for 4 662 776
proteins from 297 proteomes.
pE-DB (http://pedb.vib.be/) is the ﬁrst database for the
deposition of structural ensembles (see section 4.2) of
intrinsically disordered proteins.398 Entries contain the primary
experimental data (mainly NMR and SAXS, Box 2), the
algorithms used in their calculation, and the coordinates of the
structural ensembles, which are provided as a set of models in
Protein Data Bank147 format. Development of pE-DB is
intended to support the evolution of new methodologies for
the structural descriptions of the disordered state. pE-DB stored
45 ensembles in 10 entries as of 17 January 2014.
Finally, the Database of Disordered Protein Prediction (D2P2,
http://d2p2.pro/) stores disorder predictions (Box 3) made by
nine diﬀerent predictors for proteins from completely
sequenced genomes.49 Alongside the disorder predictions, it
contains information on MoRFs (ANCHOR386), PTM sites
(PhosphoSitePlus402), and domains (SCOP24 and Pfam22). As
of January 2014, D2P2 contained disorder predictions for 10 429
761 sequences in 1 765 genomes from 1 256 distinct species.
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combining this knowledge to gain insight into the functions of
uncharacterized proteins.
Finally, we would like to stress that it is not all about intrinsic
disorder. This Review has focused on classiﬁcations for
intrinsically disordered regions and proteins, because function
annotation for these regions is lagging behind annotation of
structured regions. However, proteins are modular, and their
functional regions can be structured or disordered, or somewhere
in between. The synergy between these fundamental building
blocks of proteins leads to combinatorial diversity of function.
Therefore, understanding how structure and disorder work
together will be crucial for uncovering the full extent of protein
function.
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Box 2. Experimental Characterization of Intrinsically
Disordered Regions and Proteins
IDPs and IDRs have been studied using a variety of experimental
techniques, including NMR, SAXS, and smFRET. Nuclear
magnetic resonance (NMR) spectroscopy is the key method to
characterize protein disorder, due to its ability to provide
residue-level information on protein structure and dynamics in
solution.403 Many aspects of structural disorder can be detected
directly using NMR, including local disorder, folding upon
binding, and disorder in complex. In contrast to NMRmethods,
detection of disorder using X-ray crystallography techniques is
mainly indirect as it relies on missing electron density.32
Another powerful method for detecting and characterizing IDPs
is small-angle X-ray scattering (SAXS), which assesses protein
dimensions and shape by measuring the scattered X-ray
intensity caused by a sample. SAXS can be used to determine
hydrodynamic parameters and the degree of globularity of a
protein, which are good indicators to determine whether a
protein is compact or unfolded.183,404 Single-molecule methods
are also emerging for the study of structural disorder.179−182
These techniques minimize averaging over the heterogeneous
ensembles of conformations in which disordered proteins
naturally exist and thus are able to measure dynamics of
individual molecules. For example, single-molecule ﬂuorescence
resonance energy transfer (smFRET) can measure dynamics
and individual conformations of the unbound ensemble,
intermediates during induced folding, and internal friction in
the folding process.180−182 Atomic force microscopy (AFM) is
also useful for the characterization of the conformational
heterogeneity of single proteins.182 High-throughput proteomic
approaches are mainly used to identify IDPs. These techniques
enrich cellular extracts for disordered proteins, and then
separate structured from disordered proteins, followed by
identiﬁcation (e.g., by mass spectrometry). For example, heat
treatment enriches cell extracts for IDPs and depletes for
proteins containing folded domains (see section 9.1).209 IDPs
can also be identiﬁed on the basis of their susceptibility to
degradation by the 20S proteasome under conditions in which
structured proteins are resistant (see section 8.3).332 The
degradation assays can be used to identify binding partners of
IDPs that provide protection against degradation. Finally,
computational techniques such as molecular dynamics (MD)
simulations complement experimental approaches and provide
important insights into IDP behavior.196,405 The DisProt,
IDEAL, MobiDB, and pE-DB databases collect experimentally
veriﬁed disordered regions and proteins (Box 1).
Box 3. Prediction of Intrinsically Disordered Regions and
Proteins
Predicting disordered regions from amino acid sequence allows
the analysis of disordered proteins at a genome-wide scale and
provides initial hypotheses about the presence of structural
disorder in individual proteins.38,406 A large number of
prediction methods have been developed and are regularly
benchmarked as part of the Critical Assessment of Techniques
for Protein Structure Prediction (CASP).407,408 Excellent
overviews of disorder prediction methods are given else-
where,406,409,410 and nonexhaustive lists of publicly available
prediction software and webservers can be found at http://en.
wikipedia.org/wiki/List_of_disorder_prediction_software and
http://www.disprot.org/predictors.php.
Three general prediction strategies currently exist:
• Disorder prediction based directly on sequence proper-
ties. For instance, IUPred is a physicochemical sequence-
based method that estimates residue interaction en-
ergies.411 Sequences with lower predicted pairwise
interaction energies are considered more likely to be
disordered due to a lack of stabilizing contacts. Similarly,
FoldIndex considers weakly hydrophobic regions of high
net charge. Such regions are likely to be disordered due to
their low energy beneﬁt when adopting a compact
conformation.31,412
• Machine learning is used in the majority of predictors, for
example, by using unresolved residues in X-ray structures
as a training set.410 For example, DISOPRED2 uses linear
support vector machines (SVMs) trained on PSI-BLAST
sequence proﬁles surrounding unresolved residues.35
Similarly, PONDR XL1 employs a feed-forward neural
network trained on sequence attributes found associated
with unresolved residues.271
• Meta-predictors that combine several individually
successful disorder prediction methods have been
developed more recently, resulting in increases in
prediction accuracy.407 For instance, metaPrDOS413
and MFDp414 both apply SVM-based machine learning
to the results of a number of individual prediction
methods to arrive at a ﬁnal score. Similarly, the
MobiDB401 and D2P2 databases49 (Box 1) provide a
consensus overview of several independent prediction
methods.
Curated databases containing experimentally determined
disordered regions, such as DisProt203 and IDEAL388 (Box 1),
provide a gold standard for assessing disorder prediction
methods. Overall, the quality of the predictions appears to have
reached a reasonable plateau of accuracy, with modest recent
progress.407,408 Additional data on biologically relevant long
disordered regions may lead to future improvements in
predicting IDRs and IDPs.408
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Box 4. Evolution of Intrinsically Disordered Regions and
Proteins
IDRs generally evolve faster than their structured counter-
parts.51−56,107 However, comparison of the rates of evolution of
structured and disordered regions in 26 protein families has
shown that this is not always the case.51 To get more insight into
the evolution of disordered regions, we predicted disorder in the
human proteome using MULTICOM-REFINE.415 We inte-
grated the disorder status of the protein residues with their
evolutionary rates across multiple sequence alignments of
homologous proteins from 53 (mostly vertebrate) species in
Ensembl Compara,1 calculated using the Rate4Site program.416
As observed previously,417 protein residues that are predicted to
be disordered generally evolve more quickly (i.e., have much
higher evolutionary rates) than those in structured regions
(Figure Box 4, P value < 10−15, Mann−Whitney U test).
However, the distributions of evolutionary rates for disordered
and structured residues are wide and overlap, which conﬁrms
that some disordered residues are conserved. In line with this, it
has been shown that particular residue types, such as Leu, Tyr,
Trp, and Pro, are more conserved in IDRs than other residue
types.53 Conserved residues and elements in IDRs are
potentially important for function and might be part of
protein−protein interaction interfaces or peptide motifs (see
section 7.1). However, sometimes, rapid divergence of
disordered regions indicates functionality, as in the case of
several human antiviral proteins (see section 7.2).
Figure Box 4. Boxplots of the distributions of evolutionary rates for
predicted structured (blue) and disordered (red) residues across the
human proteome. Residues with a high evolutionary rate are less
conserved. Boxes represent the 50% of data points in the two
quartiles above and below the median (the horizontal bar within each
box). Vertical lines (whiskers) connected to the boxes represent the
highest and lowest nonoutlier data points, with outliers being deﬁned
as >1.5 times the interquartile range from the median. Outliers are
not shown for visual clarity.
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ABBREVIATIONS
ACTH adrenocorticotropic hormone
ACTR activator for thyroid hormone and retinoid
receptors
AFM atomic force microscopy
bHLH basic helix−loop−helix domain
bRs basic regions
CARD caspase activation and recruitment domain
CASP critical assessment of techniques for protein
structure prediction
CATH class, architecture, topology, homology
CBP CREB-binding protein
Cdk cyclin-dependent kinase
CREB cAMP response element-binding protein
D2P2 database of disordered protein prediction
DBM DNA binding motif
DC space disorder-sequence complexity space
DisProt database of protein disorder
DMP1 dentin matrix acidic phosphoprotein 1
DPP dentin phosphoprotein
DSPP dentin sialophosphoprotein
dsRNA double-stranded RNA
DUF domain of unknown function
ELM eukaryotic linear motif
ER endoplasmic reticulum
ERAD endoplasmic-reticulum-associated protein degrada-
tion
FCR fraction of charged residues
FG motif phenylalanine-glycine motif
GBD GTPase-binding domain
GPCR G-protein-coupled receptor
HA hydroxyapatite
HMGB1 high-mobility group protein B1
IBSP bone sialoprotein 2
IDD intrinsically disordered domain
IDEAL intrinsically disordered proteins with extensive
annotations and literature
IDP intrinsically disordered protein
IDR intrinsically disordered region
KID kinase-inhibitory domain
MAP2 microtubule-associated protein 2
MAVS mitochondrial antiviral-signaling
MD molecular dynamics
MEPE matrix extracellular phosphoglycoprotein
MoRE molecular recognition element
MoRF molecular recognition feature
NCBD nuclear coactivator binding domain
NCPR net charge per residue
NLS nuclear localization signal
NMR nuclear magnetic resonance
NPC nuclear pore complex
OPN osteopontin
PC4 positive cofactor 4
PDB Protein Data Bank
PKR protein kinase R
POMC pro-opiomelanocortin
PPIase peptidylprolyl cis−trans isomerase
pRb retinoblastoma protein
PreSMos prestructured motifs
PSE preformed structural element
PSI protein structure initiative
PTM post-translational modiﬁcation
RLR RIG-I-like receptor
RPA70 70 kDa subunit of replication protein A
RS domain arginine-serine domain
SAXS small-angle X-ray scattering
SCF Skp, Cullin, F box
SCOP structural classiﬁcation of proteins
SCPP secretory calcium-binding phosphoprotein
SH2 Src homology 2
SH3 Src homology 3
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SIBLING small integrin-binding ligand N-linked glycoprotein
SLiM short linear motif
smFRET single-molecule ﬂuorescence resonance energy
transfer
SRSF1 serine/arginine-rich splicing factor 1
SVM support vector machine
VP16 virion protein 16
WASP Wiskott−Aldrich syndrome protein
WH2 WASP-homology domain 2
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